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1. Introduction
1.1  The c-Myc transcription factor
The c-myc proto-oncogene, which encodes the 
c-Myc	 transcription	 factor,	 was	 originally	 identified	 as	
the human homologue to the viral oncogene (v-myc) 
of the avian myelocytomatosis retrovirus more than 25 
years ago (Vennstrom et al., 1982).  Since its discovery, it 
has been implicated in a variety of human malignancies. 
c-Myc is in fact one of the most frequently activated 
oncogenes, and is estimated to be involved in 20% of all 
human cancers, affecting about 100,000 US cancer deaths 
each year (Dang, 1999) (Nesbit et al., 1999).  Due to its 
role in basic biological processes and its implications in 
tumorigenesis, the c-myc proto-oncogene has been the 
subject of intense study since its discovery, with more 
than 10,000 publications currently listed in the biomedical 
research literature.
1.1.1. c-Myc protein
The c-Myc protein belongs to the basic-
helix-loop-helix leucine zipper (HLHZip) family of 
transcription factors. The Myc transcription factor family 
also comprises N-, L-, B-, and s-Myc; nonetheless, 
only c-, N-, and L-Myc are found in mammals.  c-Myc 
is expressed ubiquitously during embryogenesis and in 
highly proliferative adult tissues.  c-Myc protein consists 
of an N-terminal transactivation domain (TAD; required 
for transcriptional activation), a central region and a 
C-terminal domain (CTD; which is critical for DNA 
binding and protein interactions) (Fig. I1).  c-Myc has 
four conserved regions known as Myc boxes (MB) that 
are essential for a variety functions.  MBI and MBII are 
found in the TAD, while MBIII and MBIV are located in 
the central region (Fig. I1).  MBI is necessary for gene 
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Fig. I1.  Structure of Myc and Max transcription factors.  Diagram of the c-Myc and Max proteins.  For c-Myc, 
the scheme details the location of the transactivation domain (TAD) containing the conserved “Myc boxes” I and II 
(MBI and MBII), the central region that harbours MBIII and MBIV, and the nuclear localisation signals 1 and 2 (NLS1 
and NLS2).  The C-terminal domain contains the basic region (b) and the helix-loop-helix leucine zipper (HLH-Zip) 
motif that is necessary for dimerisation with its obligate partner Max, and subsequent DNA binding of Myc-Max 
heterodimers.  All members of the network share the b-HLH-Zip motif.  Sid: mSin3-interaction domain.
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activation and protein degradation; MBII is critical for the 
majority of Myc’s biological functions (Oster et al., 2002) 
(Pelengaris et al., 2002) (see later); MBIII is involved 
in transcriptional repression, apoptosis, transformation 
and lymphomagenesis (Herbst et al., 2005), and MBIV 
contributes to apoptosis, transformation and modulation 
of DNA-binding (Cowling et al., 2006).  Small deletions 
or	mutations	in	any	of	 these	MB	are	sufficient	 to	affect	
Myc-dependent transactivation of target genes (Cowling 
and Cole, 2006).  In addition, the CTD contains the basic 
region (b) and the HLHZip domain.  The basic region is 
necessary for DNA binding through the consensus E-box 
sequence CACGTG, whereas the HLHZip domain is 
required for heterodimerisation with Max, the obligate 
heterodimerisation partner of Myc (see below).
1.1.2. Regulation of c-Myc protein
The regulation of c-Myc protein is controlled 
by the ubiquitin/26S proteasome pathway.  c-Myc is 
a dynamically regulated phosphoprotein with at least 
10 major phosphorylation sites spanning its length 
(Henriksson et al., 1993).  Phosphorylation of c-Myc 
has	an	important	role	in	the	transcriptional	modification,	
biological function and proteolysis of the Myc proteins. 
Two main phosphorylation sites are responsible for 
c-Myc stabilization and degradation, Ser62 and Thr58. 
Phosphorylation of Ser62 stabilises c-Myc, whereas 
phosphorylation of Thr58 leads to its degradation (Hann, 
2006).  Several studies indicate that Ser62 phosphorylation 
might be necessary for c-Myc oncogenic activity, while 
loss of Thr58 phosphorylation enhances tumorigenesis 
(Hann, 2006).  c-Myc is a short-lived protein, with a 
half-life of 20-30 minutes (Hann and Eisenman, 1984); 
disruption of proteolysis of c-Myc protein could contribute 
to tumorigenesis.  In fact, a prolonged c-Myc half-life 
has been found in a glioma cell line (Shindo et al., 1993) 
and during differentiation of an erythroleukemia cell line 
(Spotts and Hann, 1990).
1.1.3. The   Myc/Max/Mad network of transcriptional 
regulators
c-Myc protein binds to E-boxes and transactivates 
transcription of its target genes by forming a heterodimer 
to another bHLHZip protein known as Max (Blackwood 
and Eisenman, 1991).  Max is a small, ubiquitously 
expressed protein that binds to a whole collection of 
bHLHZip proteins (Baudino and Cleveland, 2001). 
c-Myc and Max form heterodimers through the HLHZip 
domain and contact DNA through the basic region (Fig. 
I1).  The Max protein lacks a TAD; consequently, Myc 
is the heterodimer partner responsible for activation of 
the transcription of its target genes (Luscher and Larsson, 
1999).  Max can also form heterodimers with bHLHZip 
proteins of the Mad/Mxi/Mnt family; these complexes 
bind the same core consensus sequence as Myc-Max 
dimers, but act instead as transcriptional repressors 
(Amati et al., 2001).  All these heterodimers are found 
in vivo, but Myc-Max complexes are predominant in 
proliferating cells, whereas Mad-Max and Mnt-Max 
complexes predominate in resting or differentiated cells 
(Ayer and Eisenman, 1993).  The working model for this 
network is therefore based on the formation of Myc-Max 
heterodimers that bind to E boxes in the promoter regions 
of	the	specific	target	genes	to	activate	their	transcription.	
Once Myc executes its biological functions, it is rapidly 
degraded, and the pathway switches to a repressive state of 
transcription where Mad-Max dimers form, bind the same 
E boxes previously occupied by Myc-Max heterodimers, 
and repress target gene transcription (Amati et al., 2001; 
Knoepfler,	2007).
1.1.4. Transcriptional activation
The expression of the majority of genes in 
eukaryotic cells is mediated by RNA polymerase II 
(polII).  DNA is normally tightly wound around histones; 
consequently, chromatin remodelling is required to allow 
transcription factors to access the promoter regions of 
genes.  For c-Myc protein, at least two mechanisms of 
chromatin remodelling have been described so far, histone 
acetylation and ATP-dependent remodelling.
In	 the	 first	 mechanism,	 c-Myc	 recruits	 a	 co-
activator complex containing transformation/transcription 
domain-associated protein (TRRAP) and histone acetyl 
transferases (HAT) such as GNC5 (McMahon et al., 
1998; McMahon et al., 2000) and TIP60 (Frank et al., 
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2003).  The HAT acetylate NH
2
-terminal lysines of 
histones located near the transcription start site (Jenuwein 
and Allis, 2001).  Acetylation opens up the chromatin 
structure, allowing enhanced transcription of Myc-
specific	 target	 genes.	 	 In	 the	 second	mechanism,	ATP-
dependent chromatin remodelling, Myc interacts with 
INI1/hSNF5 (Cheng et al., 1999), a component of the 
SWI-SNF complex that remodels chromatin in an ATP-
dependent manner.  ATP-dependent reorganization of 
the DNA induces nucleosomes to move smoothly along 
the DNA, making it more accessible (Whitehouse et al., 
1999) (Fig. I3, a).  A recent study suggests that c-Myc 
might regulate chromatin structure in a general fashion 
(Knoepfler	 et	 al.,	 2006).	 	 As	 outlined	 above,	 TRRAP	
mediates c-Myc binding to HAT TIP60 and hGCN5, 
which acetylate H4 and H3, respectively.  This study 
shows that Myc controls the genome-wide levels of H3 
and	H4	modification.		These	global	changes	in	chromatin	
structure may account for the extremely large number of 
Myc	target	genes	that	have	been	identified	so	far	–in	fact,	
Myc targets constitute nearly 10% of all cellular genes 
(Cowling and Cole, 2006).
1.1.5. Transcriptional repression
Whereas the mechanisms by which c-Myc 
activates transcription of its target genes is well 
understood, less is known about how Myc represses 
Fig. I2. Mechanisms of 
transcriptional activation and 
repression by c-Myc.  (a) Myc 
mediates transcriptional activation by 
increasing local histone acetylation 
at promoters of its target genes.  Myc 
recruits acetyltransferase complexes 
that contain TRAPP and either GCN5 
or Tip60.  These complexes alter the 
acetylation of  nucleosomes, and can 
also recruit other factors that activate 
transcription, such as the SWI/SNF 
chromatin-remodelling complex. 
(b, c) At least two mechanisms 
of transcriptional repression have 
been described; in one, (b) Inr-
dependent repression involves the 
specific	 binding	 and	 inhibition	 of	
the transcriptional activators TFII-I, 
Miz1 and YY-1 at Inr-containing 
promoters.  In the other, (c) Myc 
represses transcription of p15, p21, 
and gadd45 by a process that involves 
binding to Sp1 and/or Sp3, thereby 
inhibiting their transcriptional 
activity.
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transcription.  Most target genes that are repressed by 
c-Myc are TATA-less promoters that contain initiator 
(Inr) elements within their promoter regions; however, 
c-Myc can also mediate repression of genes that lack Inr 
elements (Gartel and Shchors, 2003).  In the case of Inr-
dependent repression, c-Myc interacts with transcriptional 
activators that bind to Inr such as TFII-I, YY1 and Miz-1, 
leading to inhibition of target gene activation (Henriksson 
and Luscher, 1996) (Fig. I3, b).  It was recently shown 
that a conserved element in MBIII is important for 
transcriptional repression (Kurland and Tansey, 2008). 
Myc represses transcription of target genes Id2 and 
Gadd153 by a process that includes histone deacetylation, 
a mechanism that involves MBIII recruitment of the 
histone deacetylase HDAC3 to the Id2 and Gadd153 
promoters.  In an Inr-independent mechanism, c-Myc also 
represses transcription of genes that lack an Inr element 
in their promoter region.  Examples of genes repressed in 
this way are gadd45 (Marhin et al., 1997), p15 (Feng et 
al., 2002) and p21Cip1 (Gartel et al., 2001).  It is thought 
that the mechanism by which c-Myc represses these 
genes is by binding to transcription factors Sp1 and Sp1/
Sp3 via the c-Myc central region, thereby inhibiting its 
transcriptional activity (Gartel and Shchors, 2003) (Fig. 
I3, c).
1.2.  The biological functions of c-Myc
The expression of c-Myc is elevated during 
embryogenesis and in adult tissues with a high proliferation 
rate, such as skin and gut.  c-Myc exerts its biological 
functions through its ability to bind to target genes and 
either activate or repress their transcription.  In recent 
years, several groups have used a variety of techniques 
to identify potential target genes.  Fig I3 summarises 
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Fig. I3. c-Myc biological functions: cell processes controlled by c-Myc during normal conditions and tumorigenesis. 
Myc	regulates	basic	cell	processes	such	as	growth	and	division	(by	regulating	chromatin	modifications	and	components	
of the biosynthetic machinery), cell cycle progression (see text), apoptosis (see text), differentiation (by downregulating 
growth arrest genes), cell metabolism (by modulating the expression of genes involved in glycolysis, amino acid 
biosynthesis and transport, synthesis of macromolecules and DNA metabolism), angiogenesis (by upregulation of 
VEGF), cell adhesion and motility (by controlling integrin expression).  Deregulation of c-Myc expression can result 
in genomic instability, uncontrolled cell proliferation, escape from immune surveillance, immortalization and growth 
factor inhibition
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the cellular processes controlled by Myc during normal 
conditions and tumorigenesis.
1.2.1. c-Myc in cell proliferation
c-Myc protein levels are highly regulated 
throughout the cell cycle; changes depend on the phase 
of the cycle in which the cell is found.  In quiescent cells 
in vitro, c-Myc expression is barely detectable.  After 
mitogenic or serum stimulation, c-Myc levels are rapidly 
induced and cells enter the G1 phase of the cell cycle. 
mRNA levels decline thereafter to low, but detectable, 
levels in proliferating cells.  If serum or growth factors 
are removed, c-Myc levels decline to undetectable levels 
and the cycle is arrested.  Numerous studies have shown 
that c-Myc regulates the cell cycle through its ability to 
activate or repress the transcription of genes involved 
in cell cycle progression.  c-Myc regulates the G1/S 
checkpoint,	and	c-Myc	expression	is	reportedly	sufficient	
to overcome the checkpoint and to induce S phase entry 
in the absence of growth factors (Eilers, 1999).  Studies 
of Rat1a c-myc-/-	 cells	 and	 in	 c-Myc-deficient	 mouse	
embryonic	fibroblasts	(MEF)	showed	that	these	cells	have	
both prolonged doubling times and G1 and G2 phases (de 
Alboran et al., 2001; Mateyak et al., 1997).
Cell cycle progression is controlled by the 
activities of the cyclin-dependent kinases (CDK) and 
the cyclin-dependent kinase inhibitors (CDKI).  c-Myc 
activates  transcription of genes involved in cell cycle 
progression such as cyclin D1, D2, E and A (Bouchard et 
al., 1999; Daksis JI, 1994; Hoang AT et al., 1994), as well 
as cdk4 (Hermeking et al., 2000) and cdc25a (Galaktionov 
et al., 1996).  c-Myc also represses transcription of cyclin 
kinase inhibitors such as p15ink4b, p21cip1 and p27kip1 (Dang, 
1999; Grandori et al., 2000).
1.2.2.  c-Myc–induced apoptosis 
The	 first	 evidence	 that	 suggested	 a	 role	 for	
c-Myc in apoptosis derived from the observation that 
ectopic	 c-Myc	 expression	 in	 fibroblasts	 in	 the	 absence	
of survival factors led to apoptosis and loss of the entire 
population (Evan et al., 1992); indeed, subsequent studies 
identified	 the	 involvement	 of	 many	 Myc	 target	 genes	
in apoptosis.  c-Myc induces apoptosis by at least four 
different	mechanisms.	 	The	first	of	 these	is	by	inducing	
cytochrome c release from mitochondria; cytochrome c 
associates with APAF1 protein, activating pro-caspase 9, 
which in turn activates the downstream caspase cascade 
and leads to apoptosis (Juin et al., 1999).  In a second 
mechanism, apoptosis is induced by activation of BAX, 
a pro-apoptotic molecule that also induces cytochrome c 
release from mitochondria (Soucie et al., 2001).  A third 
pathway is by enhancing cell sensitivity to signalling 
through the CD95 death receptor, which triggers 
association of the intracellular adaptor protein FADD 
with the CD95 receptor; FADD recruits pro-caspase 8, 
leading to activation of the caspase cascade (Hueber et 
al., 1997).  Finally, c-Myc induces apoptosis by indirect 
activation of p53 via ARF, which activates the p19/Mdm2/
p53 apoptotic pathway (Zindy et al., 1998) (Fig. I4).
The variety of c-Myc-induced apoptosis routes 
suggests that the mechanism chosen might be determined 
by several factors including cell type, tissue location and 
the presence or absence of additional mutations in other 
pro- and anti-apoptotic genes (Pelengaris et al., 2002).
1.2.3.  c-Myc and cell growth
An important aspect of proliferation is the 
capacity of the cell to increase in size and to coordinate 
this growth with division (Neufeld and Edgar, 1998). 
The means by which c-Myc controls cell growth is not 
fully understood, but it was shown that c-Myc is able 
to	 influence	 cell	 growth	 by	 binding	 to	 elements	 in	 the	
promoters of the rate-limiting translation initiator factors 
eIF4E and eIF2α (Jones et al., 1996; Rosenwald et al., 
1993).	In	addition,	c-Myc-deficient	cells	have	decreased	
protein and ribosomal RNA synthesis rates, which may 
result in reduced cell growth (Mateyak et al., 1997)
In Drosophila, c-Myc orthologue (dmyc) function 
is involved in cell size regulation.  Downregulation of 
dmyc expression	gives	 rise	 to	smaller	flies	 that	develop	
normally, as a result of a decrease in cell size and number; 
on the contrary, dmyc overexpression yield larger cells 
with a normal division rate (Johnston et al., 1999).  These 
results suggest that the effects of c-Myc on cell growth 
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are independent of those on cell division.  In mammals, 
c-Myc overexpression in B lymphocytes in Eµ-c-myc 
transgenic mice produced an increase in cell size in the 
absence of cell cycle progression (Iritani and Eisenman, 
1999).  In addition, c-myc inactivation in liver causes a 
decrease in hepatocyte size as well as smaller cell area 
(Baena et al., 2005).
Recent reports show that c-Myc also regulates 
the transcription of genes that are transcribed by RNA 
polymerase III (such as tRNA and 5S rRNA) and RNA 
polymerase I (genes encoding ribosomal RNA) (Arabi 
et al., 2005; Grandori et al., 2005).  Studies of c-Myc-
mediated transcription of RNA polymerase III-transcribed 
genes suggest that this process is Max-independent and 
therefore E-box-independent.  Consequently, c-Myc 
might act as a co-activator, rather than by binding to its 
specific	DNA	binding	site	(Gomez-Roman	et	al.,	2003).
1.2.4.  c-Myc and cell differentiation
Another important biological function of c-Myc 
is its role in cell differentiation.  c-Myc is expressed 
in immature proliferating cells, while its antagonists, 
the Mad proteins, are normally expressed in non-
proliferating and differentiated cells (Chin et al., 1995). 
Downregulation of c-myc expression is reported to trigger 
cell differentiation (Chang et al., 2000; Henriksson and 
Luscher, 1996), whereas ectopic c-myc expression blocks 
terminal differentiation in several cell types, both in 
vivo and in vitro (Facchini LM and LZ, 1998; Iritani and 
Eisenman, 1999).  Some examples of c-Myc regulation 
of cell differentiation are provided by the transcription 
Fig. I4. c-Myc and apoptosis:  different pathways of c-Myc-induced apoptosis.  (a) c-Myc can activate Bax, which 
triggers cytochrome c release from mitochondria; cytochrome c associates with APAF-1 and pro-caspase9 and activates 
the downstream caspase cascade that leads to apoptosis.  (b) c-Myc can also activate the tumour suppressor p53 via 
ARF, resulting in Bax transcription.  (c) Ligation of death receptor CD95/Fas triggers association of the intracellular 
adaptor protein FADD with the CD95 receptor.  FADD then recruits pro-caspase-8, activating the caspase cascade.
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factor C/EBPα and the B lymphocyte-induced maturation 
protein-I (BLIMP-I).  C/EBPα is necessary for myoblast 
commitment to the granulocytic lineage; it carries out 
the differentiation program by forming a complex with 
E2F/pRB that represses c-Myc expression (Johansen 
et al., 2001).  In the case of B lymphocytes, BLIMP-I 
overexpression in a pro-monocytic cell line results 
in transcriptional repression of c-myc, which induces 
differentiation to macrophages and B cells (Chang et 
al., 2000).  Overexpression of c-myc in Eµ-c-myc mice 
leads to accumulation of immature pre-B cells in the bone 
marrow of these animals (Iritani and Eisenman, 1999).
The aim of this thesis is to study the role of 
the proto-oncogene c-myc in B cell differentiation. 
The next section summarises the basic concept of this 
developmental process.
1.3.  B cell development
B cells are generated from pluripotent progenitors 
in a highly regulated process that takes place in foetal liver 
and in the adult bone marrow (BM), and further proceeds 
in the secondary lymphoid organs.  B cell development 
progresses through differentiation several stages that can 
be followed by the expression of cell surface markers 
and the rearrangement of the immunoglobulin heavy 
(IgH) and light (IgL) chain genes.  Mouse bone marrow 
contains B lineage cells at all developmental stages, from 
earliest progenitors to mature B cells.  Various approaches 
have been used to identify and isolate cells at distinct 
developmental stages based on cell surface phenotype, 
which has led to several different nomenclatures that are 
summarised in table I1.
The earliest differentiated progenitors from 
HSC (haematopoietic stem cells) with dual lymphoid 
and myeloid potential are LMPP (lymphoid-primed 
multipotent progenitors) (Adolfsson et al., 2005).  This 
population contains ELP (early lymphoid progenitors) 
with lymphoid-restricted lineage potential (Igarashi et al., 
2002); these are the precursors of CLP (common lymphoid 
progenitors), which can give rise to B, T, dendritic or 
natural killer (NK) cells (Kondo et al., 1997).  B lineage-
restricted	cells	are	identified	by	surface	expression	of	B220,	
and	arise	from	CLP.		The	first	B	lineage-committed	cells,	
Fraction A (Fr. A) or pre-pro-B cells, are characterised 
by dual expression of the B220 and CD43 cell surface 
markers, and have little or no IgH rearrangement. These 
cells proceed to Fraction B/C cells (Fr. B/C) or pro-B 
cells, characterised by CD19 surface marker expression 
and by the onset of IgH chain rearrangement.  IgH 
rearrangement	 takes	place	 in	 a	 sequential	 fashion;	first,	
a productive D
H
-to-J
H
 joining is formed, followed by 
V
H
-to-DJ
H
 rearrangement.  Productive V
H
-to-DJ
H
 joining 
Table I1. B cell nomenclature.  B cell nomenclatures and their correspondence to Hardy fractions A to E, as well 
as their IgH and IgL rearrangement status.
Phenotypic
subset Fr. A Fr. B/C Fr. C’ Fr. D Fr. E
Philadelphia
nomenclature
Pre-Pro-B Pro-B
Early
Pre-B
Late
Pre-B
New-B
Basel
nomenclature
Pro-B Pre-B-I Pre-B-I Pre-B-II
IgH GL rearranging VDJ VDJ VDJ
IgL GL GL GL rearranging VJ
Introduction
18
leads to expression of the µ chain, the hallmark of the 
pre-B cell stage, which comprises fraction C’ (Fr. C’) and 
D (Fr. D) cells.  A fraction of the µH chain is expressed 
at the cell surface of large pre-B or Fr. C’ cells, where it 
forms the pre-B cell receptor (pre-BCR) by pairing with 
the surrogate light chain consisting of λ5 and VpreB, and 
with the signalling molecules Igα and Igβ.  Pre-BCR 
expression on the surface of large pre-B cells results in a 
proliferation burst in which large pre-B cells divide further 
before giving rise to small pre-B or Fr. D cells, where IgL 
chain rearrangements take place.  Once a light chain gene 
is assembled and a complete IgM molecule is expressed 
on the cell surface, the cell becomes an immature B cell 
or Fraction E (Fr. E) cell (Fig. I5).
All the developmental stages explained above 
take place in BM and are antigen independent, but at this 
point immature B cells migrate into the periphery, where 
they are subject to selection for self-tolerance and ability 
to survive.  Surviving cells undergo further differentiation 
to become mature B cells or Fraction F (Fr. F) cells, 
characterised by surface IgM and IgD expression; these 
are also known as naïve B cells and recirculate through 
secondary lymphoid organs until they encounter their 
specific	antigen	and	are	activated.
1.4. Transcriptional control of early B cell 
development
Early B cell development in the BM of mice is 
tightly controlled by a network of transcription factors with 
specific	 roles	 in	 the	 transition	 from	 one	 developmental	
stage to the next.  Study of the genetic control of B cell 
development has been facilitated by the availability of 
mice bearing targeted mutations in genes encoding B 
cell-specific	 transcription	 factors.	 	 In	 this	 way,	 at	 least	
five	transcription	factors	were	identified	as	essential	for	B	
cell development, since their absence leads to a blockade 
in differentiation either at the initiation of B lineage 
commitment or at the onset of V
H
-to-DJ
H
 recombination. 
Ikaros and PU.1 are required for the formation of the more 
primitive lymphoid progenitors (Medina et al., 2004; Nutt 
and Kee, 2007); E2A and EBF (Medina et al., 2004) are 
important at the earliest stages of B cell differentiation, 
and Pax5 is important in the lineage commitment in 
developing B lineage cells (Nutt et al., 1999) (Fig. I6).
1.4.1  PU.1
The Sfpi1 gene encodes PU.1, a member of the 
ETS family of transcription factors, which is needed for 
the development of myeloid and lymphoid cell lineages. 
Pre-BCR
Lymphoid
progenitor
Pre-pro-B Pro-B
Large
pre-B
Small
pre-B
Immature B
Phenotypic 
fraction
A B/C C’ D E
DH JHDH JH D JHVH D JHVH
VL JL
D JHVH D JHVH
VL JL
Rearrangement
IgH and IgL
BCR
B220+
CD43+
B220+
CD43+
CD19+
B220+
CD43+
CD19+
CD25+
B220+
CD43-
CD19+
CD25+
B220+
CD43-
CD19+
IgM+
CD25-
Surface
markers
Fig. I5. B cell developmental pathway. Schematic representation of B cell development from lymphoid progenitors 
to immature B cells in the BM, showing Ig chain rearrangement status as well as the main surface markers used to 
discriminate the various developmental stages.
               Introduction
19
PU.1 is considered an important transcription factor for 
the	myeloid	versus	lymphoid	lineage	specification,	since	
low PU.1 expression levels in haematopoietic precursors 
promote lymphoid development, whereas high levels 
promote myeloid development (DeKoter and Singh, 
2000).		PU.1-deficient	mice	die	during	foetal	development	
at gestation day 18.5, and lack B, T, and myeloid 
progenitors (Scott et al., 1994).  Foetal livers of PU.1-/- 
mice have reduced numbers of progenitors with dual 
lymphoid-myeloid potential; these cells fail to proliferate 
and differentiate into pro-B cells when cultured in vitro 
with stromal cells and IL-7 (Scott et al., 1997), as they 
do not express surface IL7-Rα chain and cannot respond 
to	 IL-7	 signals	 (DeKoter	 et	 al.,	 2002).	 	 PU.1-deficient	
haematopoietic progenitors express neither the genes that 
encode the pre-BCR proteins (Igα, Igβ, λ5 and VpreB) nor 
the proteins Rag1, Rag2 or Pax5; they do express Ikaros 
and E2A, as well as EBF at very low levels (DeKoter et 
al., 2002).  Retroviral transduction of IL7-Rα into PU.1-/- 
progenitors can restore IL-7-dependent proliferation and 
differentiation in pro-B cells, but at low frequency.  It was 
recently shown that PU.1-/- fetal liver cells can give rise 
to B lineage cells when they are cultured on a stromal 
cell line and in the presence of stem cell factor (SCF), 
Flt3 ligand (Flt3L) and IL-7.  In these conditions, B cell 
colonies	 are	 nonetheless	 generated	 at	 low	 efficiency	
and with delayed kinetics compared to wild-type cells. 
These results suggest that PU.1 is not necessary for B cell 
development (Ye et al., 2005).
The generation of PU.1 conditional mutant mice 
and mice with a hypomorphic allele of Sfpi1 allowed 
study of the role of PU.1 in adult mice.  Conditional 
PU.1-/- mice have impaired haematopoiesis and excess 
granulopoiesis, do not have CLP and, in competitive 
reconstitution assays, they are unable to generate 
lymphoid cells (Dakic et al., 2005).  Moreover, when PU.1 
is deleted in CLP or in B lineage cells, there is no effect 
on B cell development (Iwasaki et al., 2005; Polli et al., 
2005).  The mice with a hypomorphic Sfpi1 allele show 
a block in B cell development from earliest precursors 
(Houston et al., 2007; Rosenbauer et al., 2006).  These 
animal models suggest that PU.1 is as an important factor 
for	lymphoid	specification,	but	is	dispensable	for	B	cell	
differentiation.
1.4.2.  Ikaros
The Ikaros gene (Ikzf1) encodes a number of 
Krüppel-type	 zinc	finger	 proteins	 that	 are	 generated	 by	
alternative splicing (Molnar and Georgopoulos, 1994) 
and can act as transcriptional activators or repressors, 
depending on cell context.  The Ikaros gene is widely 
expressed throughout the haematopoietic system, 
including haematopoietic stem cells and their committed 
progenitors (Kelley et al., 1998).  Ikaros expression 
increases in developing lymphocytes and is maintained 
in granulocytes, but is downregulated in the macrophage 
and erythrocyte lineages (Kelley et al., 1998; Klug et 
al., 1998).  Two mouse models have allowed study of 
the role of Ikaros in the transcriptional control of B cell 
development.		Ikaros-deficient	mice,	or	mice	that	express	a	
dominant negative form of Ikaros, totally lack B, NK cells 
and foetal T cells; however, a small number of early T cell 
precursors are found in the thymus, and mature T cells are 
exported to the periphery (Georgopoulos, 2002).  These 
mice do have LMPP; these cells, which are the precursors 
of CLP, retain lymphoid-myeloid differentiation potential 
(Adolfsson	 et	 al.,	 2005).	 	When	 Ikaros-deficient	LMPP	
are cultured in vitro in lymphocyte-promoting conditions, 
they cannot give rise to B cells; compared to WT LMPP, 
they generate T cells at reduced frequency and with slower 
kinetics, and also generate myeloid lineage cells (Yoshida 
et al., 2006).  These LMPP have reduced Flt3, IL7Rα and 
Rag1 expression, which could explain the impairment in 
promoting lymphoid development (Yoshida et al., 2006). 
These studies therefore indicate that Ikaros is necessary 
for initiation of the lymphoid program, but not for LMPP 
generation.
A recent paper demonstrates an essential role 
for Ikaros in regulating B cell fate commitment and 
IgH chain rearrangements. Restored EBF expression 
in	 Ikaros-deficient	 hematopoietic	 progenitors	 rescues	
B cell development in these cells, giving rise to Ikaros-
deficient	pro-B	cells	(Reynaud	et	al.,	2008).		These	cells	
express EBF and Pax5, but in the absence of Ikaros, they 
differentiate into macrophages.  Ikaros also controls 
IgH chain rearrangements at the pro-B cell stage, as it 
regulates Rag1 and Rag2 expression and compaction of 
the IgH locus.  This study suggests that Ikaros promotes 
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B cell identity by repressing alternative lineage myeloid 
genes and by inducing recombination events at the Igh 
locus.
1.4.3.  E2A
Tcfe2a encodes two splice variants, E12 and E47, 
which are members of the bHLH family of transcription 
factors (Kadesch, 1992).  With E2A, two related proteins 
(E2-2 and HEB) form the E protein family. Of these, E2A 
is	found	predominantly	in	B	lineage	cells.		E2A-deficient	
mice show a developmental block at the pre-pro-B cell 
stage (Bain et al., 1994), and fail to rearrange D
H
-to-J
H
 
segments due to the absence of Rag1 expression (Bain 
et al., 1994; Borghesi et al., 2005).  Gene expression 
studies	of	E2A-deficient	progenitors	showed	that	they	do	
express IL-7Rα, Igβ, and Igµ0; EBF is expressed at low 
levels, and there is no Pax5, CD19, Igα or λ5 expression 
(Bain et al., 1994; Bain et al., 1997).  In addition, the 
EBF promoter contains an E2A binding site, and E2A to 
activate the EBF promoter (Roessler et al., 2007; Smith 
et al., 2002).  Moreover, enforced EBF expression in 
E2A-deficient	HSC	restores	B	cell	development	in vitro 
(Bain et al., 1994; (Seet et al., 2004), although these EBF-
expressing pro-B cells cannot proliferate, since E2A is 
necessary for IL-7R-induced N-Myc upregulation (Seet et 
al., 2004).  All these data suggest that E2A acts upstream 
of EBF and Pax5 in the transcriptional control of B cell 
development.
Quite recently, the role of E2A has been studied 
throughout B cell development.  By use of a conditional 
E2A knockout (KO) mouse bred with different stage-
specific	Cre	lines,	E2A	was	demonstrated	to	be	necessary	
E2A EBF PAX5
Notch1
Flt3
IL-7R
PU.1
Ikaros
c-kit
HSC ELP CLP Pro-B
ETP Pro-T
Adapted from Roessler and Grosschedl, 2006
Fig. I6. Transcription factors regulating early B cell development.  The network of transcription factors and signalling 
components	known	to	regulate	initiation	of	the	lymphoid	program,	lineage	specification	and	commitment.		The	scheme	
represents the stage at which the absence of these factors leads to a developmental block.  Signalling pathways important 
in B cell differentiation are shown in red.  HSC, haematopoietic stem cell; ELP, early lymphoid progenitor; CLP, common 
lymphoid progenitor; ETP, early T cell progenitor.
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for the generation and development of pro-B, pre-B, and 
immature B cells in the BM and for the development of 
germinal centre B cells in the spleen, but dispensable 
for the generation of mature B cells and plasma cells in 
peripheral organs (Kwon et al., 2008).  Gene expression 
analysis	in	E2A-deficient	pro-B	cells	showed	that	Ebf1, 
Pax5, Cd19, Igα, Igβ, Igll1 levels were downregulated 
compared to those of WT pro-B cells.  E2A is therefore 
also required for maintenance of the gene expression 
program in committed pro-B cells.
1.4.4.  EBF
Early B cell factor (EBF or EBF1) is a member of 
the COE (Collier-Olf-EBF) family of transcription factors 
that bind DNA through a zinc-coordination motif found 
in the N-terminal domain (Hagman and Lukin, 2005). 
EBF also has a helix-loop-helix domain and a C-terminal 
activation domain that is not required for protein function 
(Hagman and Lukin, 2005).  EBF is considered the key 
player	 in	 the	B	 cell	 specification	 program,	 although	 its	
exact function remains unclear. It is expressed in the 
haematopoietic system from the CLP stage to mature 
cells, and its expression is turned off in plasma cells 
(Hagman and Lukin, 2005; Igarashi et al., 2002).  It is 
also expressed in brain, adipose tissue and olfactory 
neurons (Hagman et al., 1993; Wang and Reed, 1993). 
Mice	deficient	in	EBF	show	a	phenotype	similar	to	that	
of	E2A-deficient	mice;	they	do	not	express	many	B	cell-
specific	genes	such	as	Cd79a, Cd79b, Igl11, and VpreB, 
they show the same pre-pro-B cell stage developmental 
block, and have no IgH recombination in the BM.
Several functional studies have demonstrated a 
role	for	EBF	in	the	B	cell	specification	program.		Retroviral	
expression of EBF in HSC skewed differentiation 
toward the B cell lineage (Zhang et al., 2003).  Ectopic 
EBF expression rescues B cell development in E2A-
deficient	HSC	 (Bain	 et	 al.,	 1994;	 Seet	 et	 al.,	 2004),	 in	
IL-7R-deficient	 pre-pro-B	 cells	 and	 CLP	 (Dias	 et	 al.,	
2005; Kikuchi et al., 2005), and in PU1-/- HSC (Medina 
et al., 2004).  In all these cases, Pax5 expression did not 
rescue B lymphopoiesis, thus indicating that EBF might 
have additional activities during B cell development in 
addition to activation of Pax5 expression.
EBF and E2A expression are necessary for the 
initiation of B cell development; they have been shown 
to	 cooperate	 in	 the	 activation	 of	 some	 B	 cell-specific	
genes such as Cd79a, Igl11 and VpreB (O’Riordan and 
Grosschedl, 1999; Sigvardsson, 2000; Sigvardsson et 
al., 1997).  The EBF promoter has an E2A binding site 
(Smith et al., 2002), indicating that EBF might be a 
potential E2A target gene.  This suggests that EBF and 
E2A act in a feedback loop important for regulating 
specificity	of	B	cell	fate.		Two	different	EBF	promoters	
were	recently	identified,	EBFα promoter (also known as 
the distal promoter), which is active in immature B cells, 
and EBFβ promoter (known as the proximal promoter), 
active in mature B cells (Roessler et al., 2007).  Several 
transcription factor binding sites have been found on 
these promoters. The EBFα promoter is regulated by 
E2A, STAT5 and EBF, whereas the EBFβ promoter is 
regulated by ETS, PU.1, and Pax5.  This study suggests 
that EBF binding to its promoter acts as an autoregulatory 
mechanism, whereas Pax5 binding to the EBFβ promoter 
might	 amplify	 the	 B	 cell-specific	 gene	 expression	
program and early B cell precursor commitment to the B 
cell pathway.
A very recent article provided insight into EBF 
function	 in	 the	 specification	 of	 and	 commitment	 to	 the	
B lineage.  Ectopic EBF expression in LMPP and in 
Pax5-deficient	 haematopoietic	 progenitors	 promotes	 B	
cell development, blocks the myeloid potential of LMPP, 
and restricts alternative lineage potential of Pax5-/- 
haematopoietic progenitors (Pongubala et al., 2008). 
This study shows a novel, Pax5-independent function for 
EBF in the commitment of early precursors to the B cell 
lineage.
1.4.5.  Pax5
Pax5 is one of the nine mammalian Pax 
transcription factors, but is the only one expressed in 
the haematopoietic system.  The pax5 gene encodes 
the	 B	 cell-specific	 activator	 protein	 (BSAP	 or	 Pax5	
protein), a transcription factor that binds to DNA via its 
N-terminal conserved paired domain (Czerny et al., 1993) 
and controls gene transcription through a C-terminal 
module consisting of activating and inhibitory sequences 
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(Dorfler	and	Busslinger,	1996).		In	mouse,	it	is	expressed	
throughout the B cell lineage from the pro-B stage until 
its downregulation in plasma cells (Fuxa and Skok, 2007), 
and in the embryonic midbrain and adult testis (Adams 
et al., 1992).  As shown below, Pax5 has been widely 
studied and is considered to be the master regulator of 
commitment of the earliest B cell precursors in the B 
lineage, and in maintaining B cell identity throughout the 
life of a B cell before its downregulation in plasma cell 
differentiation (Fig. I7).
Pax5-deficient	 mice	 show	 a	 block	 in	 B	 cell	
development at the transition from pro-B to pre-B cells 
(Hardy fractions B to C) (Urbanek et al., 1994).  Pax5-
deficient	pro-B	cells	have	been	subject	of	intense	study.	
These cells show normal D
H
-to-J
H
 and V
H proximal
-to-DJ
H
 
rearrangements, but impaired V
H distal
-to-DJ
H
 recombination 
(Nutt	et	al.,	1997).		They	can	also	be	expanded	indefinitely	
in vitro in the presence of IL-7 and a stromal cell line, 
although they are unable to give rise to mature B cells (Nutt 
et	al.,	1997).		Unlike	WT	pro-B	cells,	Pax5-deficient	cells	
are uncommitted progenitors that, when cultured in vitro 
with the appropriate cytokines, can give rise to functional 
cells of all other lineages except B lymphocytes (Nutt et 
al.,	1999).		Pax5-deficient	cells	show	the	same	plasticity	
in vivo.  When in vitro-cultured or ex vivo	Pax5-deficient	
cells are transferred into Rag2-/- mice, they provide long-
term reconstitution of T cell development (Rolink et al., 
1999).  Another study showed that when these cells are 
injected into lethally irradiated mice, they are able to 
migrate to the BM and reconstitute all haematopoietic 
lineages except B lymphocytes (Schaniel et al., 2002). 
Gain-of-function studies have shown that restoration of 
Pax5	expression	in	deficient	cells	suppresses	this	multi-
lineage potential, and cells can differentiate into mature B 
cells (Nutt et al., 1999), whereas conditional inactivation 
of Pax5 in pro-B cells reverses lineage commitment and 
again generates multipotent cells (Mikkola et al., 2002). 
Lymphoid
progenitor
pro-B pre-B Mature B
Pax5 -/- Pax5 +/+
- Activates expression of B cell-specific genes
- Represses expression of B-cell innapropriate genes
- Regulates VH-to-DJH recombination at the IgH locus
Pax5 expression
Plasma cell
Macrophage
NK cell T cell
Erythrocytes
Adapted from Carotta and Nutt, 2008
Fig. I7.  Biological functions of the Pax5 transcription factor.  Pax5 is considered necessary for B lineage 
commitment.  It is expressed throughout B cell development, from pro-B cells until its downregulation in plasma 
cell	 differentiation.	 	 Pax5-deficiency	 leads	 to	 a	 block	 at	 the	 pro-B	 cell	 stage	 (vertical	 red	 line),	 these	 cells	 are	
uncommitted and can give rise to cells of other haematopoietic lineages.  The biological functions of Pax5 are listed 
in the right panel.
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It was recently shown that when Pax5 is inactivated in 
vivo in mature B cells of peripheral lymphoid organs, 
cells are able to dedifferentiate to early uncommitted 
progenitors that can home to BM (Cobaleda et al., 
2007).  These dedifferentiated progenitors are able to 
differentiate into macrophages and to rescue T cell 
development	 in	T	 cell-deficient	mice.	 	Moreover,	 these	
B cell-derived T lymphocytes show both IgH and IgL 
chain rearrangements and can participate as functional T 
cells in immune reactions (Cobaleda et al., 2007).  These 
dedifferentiated	 Pax5-deficient	 cells	 also	 develop	 into	
aggressive lymphomas with a phenotype similar to Pax5-
deficient	pro-B	cells,	but	with	rearranged	IgH	and	IgL	gene	
segments.  Overall, this study provided further evidence 
of the requirement for continuous Pax5 expression to 
maintain B cell identity at later differentiation stages.
Pax5 activates the expression of multiple B cell-
specific	genes,	including	those	encoding	the	cell	surface	
protein CD19 (Kozmik et al., 1992), the signalling 
molecule Igα (CD79a) (Fitzsimmons et al., 1996), 
the surrogate light chains λ5 and VpreB (Okabe et al., 
1992), the adaptor protein of pre-BCR signalling BLNK 
(Schebesta et al., 2002), and the transcription factors 
N-Myc and LEF-1 (Nutt et al., 1998).  Pax5-repressed 
genes include the macrophage colony stimulating-factor 
receptor (M-CSFR, encoded by Csf1R) (Nutt et al., 1999), 
Notch1 (Souabni et al., 2002), and FLt3 (Holmes et al., 
2006).
All of these studies suggest that the transcriptional 
control of early B cell development is not a linear 
mechanism in which each transcription factor actis at 
a given developmental stage.  It is becoming clear that 
the	 commitment	 of	 lineage-specific	 progenitors	 to	 a	
particular fate is dependent on dose, combination, and 
cross-competition among these factors.  Moreover, there 
is a continuous need for the expression of some of these 
transcription factors to reinforce the commitment process 
throughout a B cell’s life.
1.5.  c-Myc and B lymphopoiesis
The role of c-Myc in B cell development is poorly 
understood, mainly because of the redundancy of related 
transcription family members that might compensate 
the c-myc expression defect.  Only c- and N-myc are 
expressed in mammalian B lymphocytes; in addition, 
c-myc is expressed at different levels throughout the 
differentiation process.  Expression begins at the pro-B 
cell stage, induced in response to cytokines such as IL-7 
(Morrow et al., 1992).  It is also expressed, together 
with N-myc, in large pre-B cells during maturation and 
expansion to small pre-B cells (Zimmerman and Alt, 
1990).  Thereafter, only c-myc is expressed in immature 
and mature B cells after B cell activation.
Studies of several B cell lines have shown 
that c-myc up- or downregulation results in apoptosis 
(Thompson, 1998).  In immature B cell lines, such as 
WEHI-231 or CH31, apoptosis is induced after anti-
IgM crosslinking.  BCR stimulation induces a transient 
increase in c-myc levels, which return to basal levels after 
4 hours.  In these cell lines, stabilisation of c-Myc levels 
or c-Myc overexpression protects cell from apoptosis 
induced by anti-IgM treatment (Fischer et al., 1994; Wu 
et al., 1996).  c-Myc downregulation is thus necessary for 
immature B cell lines to undergo apoptosis.  In mature B 
cell lines, on the other hand, in which c-myc expression 
is very low, BCR stimulation induces upregulation of 
c-Myc, eventually leading cells to apoptosis (Kelly et al., 
1983).
Gain-of-function studies using a murine model 
of lymphomagenesis (Eµ-myc mice) have been used to 
study c-Myc in B cells.  Constitutive expression of a c-myc 
transgene under the control of the heavy chain enhancer 
(Eµ)	results	in	impaired	B	lymphopoiesis,	reflected	in	an	
increase in pro- and pre-B (IgM-) cells and in a reduction 
of immature and mature B cells (IgM+) in BM.  A reduction 
in spleen B lymphocytes is also observed, which is 
attributed to impaired B cell development in the BM or to 
an increase in apoptotic cells due to inappropriate c-myc 
expression (Iritani and Eisenman, 1999).  In addition, B 
cells from both BM and spleen show an increase in cell 
size, which is independent of their developmental stage 
and is found at all cell cycle phases.  This cell size increase 
correlates with increased protein synthesis in normal pre-
transformed B lymphocytes at all B cell developmental 
stages (Iritani and Eisenman, 1999).
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The use of mouse conditional KO models has 
provided greater understanding of the in vivo function of 
the proto-oncogene c-myc in B lymphocytes.  c-Myc was 
shown to affect B cell proliferation and apoptosis.  Initial 
studies showed that c-Myc is necessary for proliferation 
of primary B cells (de Alboran et al., 2001).  When 
c-Myc-deficient	mature	B	lymphocytes	are	cultured	with	
mitogenic stimuli, cells accumulate in the G0/G1 phase 
and show a shortened S phase.  These cells have increased 
levels of the cell cycle inhibitor p27, which could explain 
the proliferation impairment at least in part (de Alboran et 
al.,	2001).		c-Myc-deficient	B	lymphocytes	are	also	more	
resistant to various apoptotic stimuli.  Non-activated 
c-Myc-deficient	B	cells	are	resistant	to	spontaneous	cell	
death, whereas activated cells are resistant to CD95-
induced cell death (de Alboran et al., 2003).  When c-Myc-
deficient	B	cells	are	activated	by	mitogenic	stimuli,	they	
express normal surface levels of activation markers, but 
reduced CD95 and CD95L levels.  The role of c-Myc 
in B cell development has recently been studied using 
double c- and N-myc KO mice, showing that conditional 
myc deletion notably inhibits B cell development at 
the pro-B to pre-B cell transition (Habib et al., 2007). 
Another approach showed that c-Myc expression 
rescues the developmental block in differentiation in 
the absence of pre-BCR formation.  As Ca2+ signalling 
is an important pre-BCR-induced event, these authors 
also analyzed whether c-Myc expression had an effect 
on Ca2+ mobilisation; they found that Myc might promote 
proliferation and differentiation of primary B cells by 
amplifying Ca2+ signalling, which enables expression of 
both Myc and Ca2+-regulated genes, which are essential 
for cell division and differentiation.
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      2.  Aims
1. To characterise the developmental block in B cell differentiation due to c-myc inactivation.
2. To identify potential c-Myc target genes in B lymphocyte differentiation.
3. To perform gain-of-function studies with potential c-Myc targets to rescue the phenotype in c-Myc-
deficient	B	lymphocytes.
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Materials & Methods
3. Materials & Methods
3.1.  Mice.  
Generation of c-mycfl/fl; mx-cre+ mice was described 
previously (Baena et al., 2005).  To generate c-mycfl/
fl; mb1cre/+, we bred c-mycfl/fl with mb1cre/+mice (Hobeika et 
al., 2006) and crossbred their progeny to yield homozygous 
(c-mycfl/fl; mb1cre/+) and control mice (c-mycfl/+; mb1cre/+ or 
c-mycfl/fl; mb1+/+).		Briefly,	c-mycfl/fl; mb1cre/+ were bred with 
rosa26gfp/gfp mice (Mao et al., 2001), and progeny crossbred 
to yield homozygous c-mycfl/fl; mb1cre/+; rosa26gfp/gfp or 
heterozygous c-mycfl/+; mb1cre/+; rosa26gfp/gfp mice.
Briefly,	c-mycfl/fl; mx-cre+ or c-mycfl/fl; mb1cre/+ mice were 
bred with Ikneo/+ mice (Souabni et al., 2002) to generate 
Ikneo/+; c-mycfl/fl; mx-cre+ or Ikneo/+; c-mycfl/fl; mb1cre/+, 
respectively.  Progeny was crossbred to generate 
homozygous (Ikneo/+; c-mycfl/fl; mx-cre+ or Ikneo/+; c-mycfl/
fl; mb1cre/+) control mice (Ikneo/+; c-mycfl/fl; mx-cre- or 
Ikneo/+; c-mycfl/+; mb1cre/+).
Mice were genotyped using a PCR-based analysis of 
tail genomic DNA (de Alboran et al., 2004; Baena et al., 
2005).
3.2.  Genomic PCR.  
Primers	used	to	amplify	the	floxed	allele	(530	bp	product)	
were FloxS (5’- GCC CCT GAA TTG CTA GGA AGA 
CTG-3’) and FloxA (5’-CCG ACC GGG TCC GAG TCC 
CTA	TT-3’).	The	deleted	allele	(∆,	600	bp)	was	amplified	
with primers Null S (5'-TCG CGC CCC TGA ATT GCT 
AGG AA-3') and Null A (5'-TGC CCA GAT AGG GAG 
CTG TGA TAC TT-3').   The mx-cre transgene (269 bp 
product)	was	amplified	with	primers	SF-4	(5’-	GCA	TAA	
CCA GTG AAA CAG CAT TGC TG-3’) and 69-R (5’- 
GGA CAT GTT CAG GGA TCG CCA GGC G-3’).
Primers hcre-DIR (5’- ACC TCT GAT GAA GTC AGG 
AAG AAC-3’), hcre-REV (5’- GGA GAT GTC CTT CAC 
TCT GAT TCT-3’), mb1in1 (5’- CTG CGG GTA GAA 
GGG GGT C-3’) and mb1in2 (5’- CCT TGC GAG GTC 
AGG GAG CC-3’) were used to amplify mb1-cre (hcre-
DIR and hcre-REV, 600 bp PCR product) and mb1-WT 
alleles (mb1in1 and mb1in2, 550 bp PCR product).  The 
knock-in allele  (Ikneo/+)	was	identified	by	a	780	bp	PCR	
fragment using Ikneo-5’ (5’- GCG GAG CTC CTC AGG 
TGC AGG CTG CCT ATC- 3’) and Ikneo-3’ (5’- CGC 
GTC GAC GCT AAC ATC CTG AGG GAC TGT-3’) 
primers.
3.3.  PipC injections. 
To induce c-myc deletion in c-mycfl/fl; mx-cre+ and 
Ikneo/+; c-mycfl/fl; mx-cre+ mice, 4- to 6-week-old mice were 
given three intraperitoneal (i.p.) injections of polyinosinic-
polycytidylic acid (pIpC, Amersham) (150 µg each, or 
250 µg each for in vitro differentiation experiments) at 
two-day intervals and analyzed 3 or 5 days after the last 
dose.
3.4.  Flow cytometry sorting and analysis.  
Single-cell suspensions of bone marrow (BM) cells, 
isolated from femurs and tibias, and of spleens were 
resuspended	in	PBS	containing	2%	FBS.		Cells	were	first	
incubated for 10 min on ice with FcBlock (Beckman) to 
avoid	non-specific	antibody	binding.		Subsequently,	cells	
were incubated (15 min, on ice) with primary antibodies, 
washed, and biotin-stained cells were incubated with 
secondary antibodies (15 min, on ice).  Primary antibodies 
were B220 conjugated to PeCy7 (Bioscience), FITC 
or APC (Becton Coulter), IgM-PE or -biotin (Southern 
Biotechnologies), CD19-APC (Becton Coulter), and 
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CD25-PE, CD43-biotin, CD117-PE or pre-BCR-biotin 
(all from Pharmingen).  Streptavidin-APC (Pharmingen) 
or -ECD (Immunotech) were used as secondary 
antibodies.  B lymphocytes from BM were sorted as 
B220+IgM- (pro- and pre-B cells), B220lo IgM+ (immature 
cells) and B220hiIgM+ (mature cells) on a FACS Coulter 
flow	cytometer.		The	purity	of	the	sorted	populations	was	
verified	by	flow	cytometry	reanalysis	as	>97%.
3.5.  Apoptosis analysis. 
BM cells were isolated and stained as described above, 
and apoptosis analysis was performed using FITC- or PE-
annexin V (Immunotech and Becton Coulter, respectively) 
and propidium iodide (PI) staining according to the 
manufacturer’s protocol.
3.6.  BrdU labelling.  
Analysis of BrdU incorporation into BM cell populations 
was assessed 2 h after a single intravenous BrdU injection 
(1 mg/15 g body weight, Sigma).  B220+IgM- (pro-B cells), 
B220lo IgM+ (immature cells) and B220hiIgM+ (mature 
cells) cells were sorted from BM, and BrdU incorporation 
measured using FITC- or PE- anti-BrdU monoclonal 
antibody (Becton Dickinson, Mountain View, CA, USA) 
and PI, following standard protocols.
3.7.  Gene expression analysis.  
RNA from sorted B220+IgM- cells (1.5-2 x 105 cells) was 
extracted using the RNeasy Micro kit (Qiagen) according 
to the manufacturer’s protocol.  First-strand cDNA was 
primed with random primers (Promega) from whole 
sample RNA using the Reverse Transcription System 
(Promega).  For real-time PCR analysis, 2.5 µl cDNA 
was mixed with primers and SYBR Green PCR master 
mix (Becton Dickinson) following the manufacturer’s 
instructions.  cDNA was used in a  tenfold dilution series 
(10- and 100-fold).  Reverse transcription-PCR was on 
an ABI Prism 7700HT and was analyzed with SDS 1.9 
sequence detection system (Applied Biosystems).  All 
oligonucleotides were designed to yield 50-100 bp PCR 
fragments. Oligonucleotides for c-myc were c-mycRT-5’ 
(5’- TGC CTC TTC TCC ACA GAC AC-3’) and 
c-mycRT-3’ (5’- TCT GTA CCT CGT CCG ATT C-3’), 
for Tcfe2a, E2A-F (5’- AAG AGG ACA AGA AGG ACC 
TGA A-3’) and E2A-R (5’- TTA TTG GCC ATA CGC 
CTC TC-3’), EBF1-F (5’- CAG GAA ACC CAC GTG 
ACA T-3’) and EBF-R (5’- CCA CGT TGA CTG TGG 
TAG ACA-3’) for ebf;  primers for cd19 were CD19-F 
(5’- AAG GTC ATT GCA AGG TCA GC-3’) and 
CD19-R (5’- CTG GGA CTA TCC ATC CAC CA) ,for 
actin primers were actin1 (5’- AAG GAG ATT ACT GCT 
CTG GCT CCT A-3’) and actin2 ( 5’- ACT CAT CGT 
ACT CCT GCT TGC TGA T-3’), and 28s-5’ (5’- TGC 
CAT GGT AAT CCT GCT CA-3’) and 28s-3’ 85’- CCT 
CAG CCA AGC ACA TAC ACC-3’) for 28s.
Pre-designed Applied Biosystems Micro Fluidic cards 
containing cDNA samples and reagents were run on an 
ABI Prism 7900HT.  Data were analyzed with SDS2.2 
sequence detection systems.
3.8.  Cell isolation and culture.  
B cell cultures were established from BM cell suspensions 
from 4- to 8-week-old mice by depletion using antibodies 
to IgM (Southern Biotechnologies) and Streptavidin 
Dynabeads (Invitrogen).  Purity of cells after magnetic 
separation	was	 confirmed	 by	 flow	 cytometry	 as	 >98%.	
Cells were cultured in 24-well plates (2 x 106 cells/
ml)	 in	 Iscove’s	Modified	Dulbecco’s	Medium	 (IMDM) 
containing 2% heat-inactivated foetal bovine serum (FBS), 
1 mM L-glutamine, 1 mM penicillin/streptomycin, 0.03% 
w/v	primatone	RL	(Sigma),	50	µM	β-mercaptoethanol)	
and supplemented with recombinant murine stem cell 
factor (SCF, 10 ng/ml), recombinant murine FLt3 ligand 
(FLt3L, 10 ng/ml) and recombinant murine IL-7 (10 ng/
ml), all from PeproTech.
To isolate lineage-negative precursors, BM cells were 
incubated with a cocktail of biotinylated antibodies to 
lineage markers (B220, IgM, CD4, CD8, Ter119, Gr1 and 
CD11b, all from Pharmingen) and Streptavidin Dynabeads 
(Invitrogen).  Cells were cultured at 106 cells/ml in 24-
well	 plates	 in	 Dulbecco’s	 Modified	 Eagle’s	 Medium	
(DMEM) containing 10% heat-inactivated FBS, 1 mM 
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L-glutamine and supplemented with recombinant murine 
stem cell factor (SCF, 5 ng/ml), recombinant murine IL-6 
(2.5 ng/ml) and murine leukemia inhibitory factor (LIF, 
103 units/ml).
Cells were incubated in standard conditions (37°C, 5% 
CO
2
, 96% relative humidity) for up to one week and the 
percentage of pro-B, immature and mature B lymphocytes 
was assessed by FACS at days 4 and 7 of culture.
3.9.  Retrovirus production and transduction.  
PLAT-E cells were maintained in DMEM containing 
10% heat-inactivated FBS, 1 mM L-glutamine, 1 mM 
penicillin/streptomycin, 1 µg/ml puromycin (Clontech) 
and 10 µg/ml blasticidin (Invitrogen).  PLAT-E cells 
were seeded (2 x 106 cells) in 6-cm plates, 18-24 h before 
transfection with FuGene 6 reagent (Roche Diagnostics). 
MIG-RI or MIG-EBF (3 µg) were transfected to each 
plate containing PLAT-E cells.  After 24 h, medium was 
replaced by complete IMDM without cytokines.  Retroviral 
supernatants were collected 48 h post-transfection and 
filtered	 through	 a	 45	 µm	 low	 protein-binding-	 syringe	
filter	(Pall,	Life	Sciences).
Pre-stimulated BM cells and lineage precursors were 
transduced by spin infection after 1 day in culture.  Cells 
were resuspended in 1 ml of fresh retroviral supernatant, 
supplemented with 10 µg/ml polybrene (Sigma-Aldrich) 
and cytokines at the same concentration as above.  Cells 
were centrifuged at 2000 rpm (90 min, 32ºC).  After 
centrifugation, cells were placed at the incubator (3-4 
h), after which medium was replaced by fresh IMDM 
plus cytokines (SCF, Flt3L and IL-7, 10 ng/ml each). 
Transduction	efficiency	was	monitored	by	FACS	at	48	to	
72 h post-infection.
3.10.  Titration of retroviral supernatants.  
Retroviral supernatants generated on 293T cells were 
titrated	 in	NIH3T3	fibroblasts.	At	24	h	before	 infection	
1.5 x 105 cells were plated in each well of a 6-well plate. 
On the day of infection, viral supernatants were diluted 
10-fold in complete DMEM medium supplemented with 
polybrene (10 µg/ml, Sigma-Aldrich) and added to target 
cells.  Cells were incubated (6 to 8 h) and medium was 
replaced by fresh DMEM.  At 48 h post-infection, cells 
were	collected	and	analyzed	by	flow	cytometry	for	GFP	
expression.
The following formula was applied to calculate virus titre: 
titre (IU/ml) = number of target cells at day of infection X 
(percentage of GFP-positive cells)/100 X dilution factor.
3.11.  Clonogenic assays.  
Purified	 B220+CD43+ cells from each genotype 
(5 x 103 cells/plate) were seeded into methylcellulose-
containing media.  To assess generation of BFU-E, 
cells were plated into MethoCult 3234 (Stem Cell 
Technologies, Vancouver, Canada) supplemented with 
10 ng/ml murine IL-3 (Biosource, Worcester, MA), 3 
U/ml human recombinant erythropoietin (Stem Cell 
Technologies) and 50 ng/ml murine SCF (Peprotech). 
For generation of CFU-GM and CFU-preB precursors, 
cells were seeded into MethoCult M3534 and MethoCult 
M3630, respectively (both from Stem Cell Technologies). 
CFU-GM and CFU-preB colonies were scored on day 7, 
and BFU-E colonies on day 9.
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4.  Results
4.1. Animal models for the study of c-myc function 
in B lymphocytes
Germ line inactivation of c-myc causes 
embryonic lethality at day E9.5-10.5.  For this reason, 
the development of conditional knockout mice enables 
study of the function of this proto-oncogene in vivo. 
We used the c-mycfl/fl mice (de Alboran et al., 2001), 
based on the cre-loxP strategy; breeding them with 
mice	carrying	a	stage-specific	Cre recombinase gene 
permits analysis of the in vivo function of c-myc in 
early B lymphopoiesis.
To study the role of the proto-oncogene c-myc 
in B cell development, we generated two animal models 
that delete c-myc in developing B lymphocytes, in 
either a constitutive or an inducible way.  Generation 
of c-mycfl/fl mice was previously described (de Alboran 
et	al.,	2001).		Briefly,	loxP sites were inserted between 
exons 2 and 3 in the mouse germ line c-myc locus (Fig. 
R1).  Mice homozygous for this mutation showed no 
phenotype in the absence of the Cre recombinase 
(Baena et al., 2005).  Activation of Cre recombinase 
leads to complete inactivation of the c-myc gene by 
deletion	of	the	sequence	flanked	by	the	two	loxP	sites	
(de Alboran et al., 2001)(Fig. R1).
4.1.1. Constitutive model: c-mycfl/fl; mb-1cre/+
To study c-myc function in B lymphocytes, we 
bred c-mycfl/fl with the mb-1cre/+ knock-in mice (Hobeika 
et al., 2006), which have the Cre recombinase gene 
under the control of the mb-1 promoter.  The mb-1 gene 
encodes the Igα subunit of the pre-B cell receptor (pre-
a
1 2 3
RI RI RI
c-mycWT
c-mycFlox
cre recombinase
1
RI RI
c-mycNull
Loxp Loxp
1 2 3
RI RI RI
Fig. R1.  Structure of the targeted flox locus.  The c-myc	gene	flanked	by	two	loxP sites inserted between 
exons 2 and 3.  Cre- mediated recombination generated a null c-myc allele that lacks exons 2 and 3.  RI, EcoRI 
restriction sites; red arrowheads indicate loxP sites; green rectangles show coding exons; black rectangles show 
non-coding exons.
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BCR) and is expressed exclusively in B cells beginning 
at the early pro-B cell stage in the BM (Hobeika et 
al., 2006).  F2 generation intercrosses generated 
homozygous c-mycfl/fl; mb-1cre/+ and littermate controls 
c-mycfl/+; mb-1cre/+ (Fig.R2a).  c-mycfl/fl; mb-1cre/+ mice 
inactivate c-myc	 constitutively	 and	 specifically	 in	
B lymphocytes, making them a perfect mouse model 
in which to study the role of the proto-oncogene c-myc 
in B cell development.
To	 track	 c-Myc-deficient	 B	 cells	 by	 the	
expression	of	green	fluorescent	protein	(GFP),	c-mycfl/
fl; mb-1cre/+ mice were bred with the rosa26gfp/gfp reporter 
mice (Mao et al., 2001)(Fig. R2a), which express 
b
a
Early 
progenitors Pro-B Immature B Mature B
mb1-cre
mx-cre
a
X
F2
c-mycFlox/Flox
mx-cre+
mb-1cre/+
mb-1cre/+
c-mycFlox/Flox;
mx-cre+
(inducible)
c-mycFlox/Flox;
mb-1cre/+
(constitutive)
c-mycFlox/Flox;
mb-1cre/+; rosa26gfp/gfp
(constitutive)
X
F3
F2
rosa26gfp/gfp
Fig. R2. Scheme showing the mouse models used to study c-myc function in B cell development.  (a) 
c-mycflox/flox mice were bred with different Cre recombinase strains to produce several mouse models that 
inactivate c-myc at different time points during B cell development.  (b) Time-course c-myc inactivation in 
BM in two of the mouse models.
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enhanced GFP (eGFP) under the endogenous promoter 
of the rosa26 gene.  Cre recombinase expression by 
the endogenous mb-1 locus leads to deletion of both 
the c-myc locus and the stop codon inserted in the egfp 
gene in immature B lymphocytes.  This strategy allows 
us	to	distinguish	c-Myc-deficient	cells	from	undeleted	
cells based on GFP expression, and therefore to select 
and	isolate	c-Myc-deficient	B	cells	(de	Alboran	et	al.,	
2004).
4.1.2.  Inducible model: c-mycfl/fl; mx-cre+ mice
c-mycfl/fl; mx-cre+ mice have been described 
(Baena	et	al.,	2005).		Briefly,	c-mycfl/fl mice were bred 
with the mx-cre transgenic mice (Kuhn et al., 1995), 
which carry the Cre recombinase gene under the 
control of the inducible promoter of the murine mx1 
gene.  Mx1 is part of the defence against viral infections 
and is silent in healthy mice.  The mx1 promoter is 
activated transiently in several tissues after injection 
of α or β interferon or polyinosinic-polycytidylic acid 
(pIpC), a synthetic double-stranded RNA that acts as 
an interferon inducer.  The F2 generation originated 
homozygous c-mycfl/fl; mx-cre+ mice, which inactivate 
the c-myc gene following pIpC treatment (Fig. R2a). 
After pIpC injection, c-mycfl/fl; mx-cre+ mice show 
c-myc	inactivation	in	several	organs.	Efficient	deletion	
of c--myc (80-100%) is found in bone marrow (BM) 
(Baena et al., 2005), making this animal model 
suitable for the study of c-myc in BM hematopoiesis, 
and therefore of early B lymphopoiesis.
It is important to note the differences between 
these two models.  Whereas c-mycfl/fl; mb-1cre/+ mice 
begin to inactivate c-myc	specifically	at	the	pro-B	cell	
stage, c-mycfl/fl; mx-cre+ delete the c-myc gene from the 
earliest progenitors in the BM (Fig. R2b).
4.2.  c-Myc function in B cell development
The c-myc proto-oncogene is expressed in both 
immature and mature B cells (Leider and Melamed, 
2003).		Our	first	objective	was	therefore	to	characterise	
the	different	B	cell	subsets	 found	in	c-Myc-deficient	
BM.  B lymphopoiesis in the BM can be followed by 
the expression of several cell surface markers, as well 
as by the immunoglobulin gene rearrangement that 
takes place in a sequential and ordered way.  Among 
the B220+IgM-CD43+ population, several subsets are 
identified:	Fraction	A	(Hardy	et	al.,	1991)	or	pre-pro-B	
cells, the least-committed B cell population, pro-B 
cells (or Fraction B/C), and pre-B cells (Fraction D). 
Within the B220+IgM+CD43+ population, immature 
B (Fraction E) and mature B cells (Fraction F) are 
found.
4.2.1.  c-Myc is necessary for B cell development
To study c-myc function in B cell development, 
we analysed 5- to 10-week-old c-mycfl/fl; mb-1cre/+ mice 
that, as explained above, delete c-myc specifically	in	B	
cells at the pro-B cell stage.  To characterise the distinct 
B cell subsets, we studied the surface expression 
markers	 defined	 by	Hardy	 and	 colleagues	 (Hardy	 et	
al., 1991).  Analysis of total BM (tBM) showed that 
both the B220+CD43- and B220+IgM+ populations 
were absent in the BM of c-mycfl/fl; mb-1cre/+ mice (Fig. 
R3a).  In wild-type mice, a B220 versus IgM plot 
(Fig. R3a, upper panel) indicates three populations: 
the B220+IgM- population comprised of Hardy 
Fractions A-D (or pro- and pre-B cells), B220lowIgM+, 
corresponding to Fraction E (or immature B cells), 
and B220hiIgM+ Fraction F (or mature B cells).  In 
c-mycfl/fl; mb-1cre/+ mice, this plot showed that c-Myc-
deficient	B	 lymphocytes	were	unable	 to	differentiate	
beyond the B220+IgM- stage of B cell development. 
Absolute numbers showed that the B220+ population 
was reduced by three-fold (4.5 x 106 vs. 1.3 x 106 
cells), whereas B220+IgM- cells were reduced by two-
fold (2.4 x 106 vs. 1.2 x 106 cells) in the BM of c-mycfl/
fl; mb-1cre/+ mice compared to control littermates 
(Fig. R3b).  The B220 versus CD43 plot (Fig. R3a, 
lower panel) permits a more detailed analysis, as it 
differentiates Fractions A, B, C and C’ (found in the 
B220+CD43+ population) from Fractions D and E (in 
the B220+CD43+ population).  These data showed 
that	 c-Myc-deficient	 B	 lymphocytes	 were	 unable	 to	
differentiate beyond the Fraction C stage.
Genomic PCR on sorted B220+IgM-GFP+ cells 
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from c-mycfl/fl; mb-1cre/+; rosa26gfp/gfp mice showed that 
c-myc was deleted in these cells (Fig. R3c).  FACS 
analysis of various cell surface markers indicated that 
GFP-positive cells in these mice were exclusively B 
cells (Fig. R3c), indicating that c-myc is deleted solely 
in B cells.
We next characterised B cells in the spleen of 
c-mycfl/fl; mb-1cre/+; rosa26gfp/gfp mice.  For this purpose, 
splenocytes	 were	 stained	 with	 fluorescence-labelled	
antibodies to B220 and IgM surface markers, which 
allow the characterisation of B lymphocytes in the 
spleen.  Staining showed that spleen mature B cells 
(B220+IgM+) were greatly reduced in homozygous 
mice compared to control littermates (3.5% vs. 
35.6%; 10.2-fold decrease) (Fig. R3d).  Genomic 
PCR on sorted B220+IgM-GFP+ cells showed that that 
c-myc was deleted in these cells (Fig. R3e).  There 
are two possible explanations for this phenomenon. 
One is that some cells that inactivate c-myc are able 
to differentiate, migrate into the blood stream and 
colonise the spleen; the other is that since the mb-1 gene 
is expressed at every stage of B cell development and 
activation, excluding terminally differentiated plasma 
cells (Hobeika et al., 2006), B220+IgM+ cells in the 
homozygous mouse spleen could escape c-myc deletion 
at the pro-B cell stage and inactivate c-myc once they 
reach the spleen.  Concurring with the staining results, 
the absolute numbers of B220+IgM+ cells showed a 
16.8-fold decrease in c-mycfl/fl; mb-1cre/+; rosa26gfp/gfp 
compared to control c-mycfl+l; mb-1cre/+; rosa26gfp/gfp 
mice (Fig. R3d).
B lymphocytes can be maintained and 
expanded in vitro when they are co-cultured with a 
stromal cell line and certain exogenous cytokines.  Flt3 
ligand, stem cell factor (SCF), and IL-7 are important 
cytokines for B cell development (Mackarehtschian et 
al., 1995) (Sitnicka et al., 2003).  
To determine whether the B220+IgM+ cells in 
the	 spleens	 of	 c-Myc-deficient	mice	were	 generated	
in the absence of c-myc, BM cells were depleted of 
IgM-positive cells and cultured with the Flt3L/SCF/
IL-7 cytokine cocktail.  After 3 or 4 days in culture, in 
vitro differentiation was assessed by FACS analysis. 
We performed these experiments with both c-mycfl/
fl; mb-1cre/+ and c-mycfl/fl; mb-1cre/+; rosa26gfp/gfp BM cells. 
In both cases, we found that after 3 days in culture, 
there was substantial B cell enrichment in the cultures, 
as assessed by B220 vs. IgM and B220 vs. CD19 
plots.  Whereas in the case of WT cells, differentiation 
proceeded through B220+IgM+ and B220+CD19+ 
cells,	 in	 c-Myc-deficient	 BM	 cells	 were	 blocked	 at	
the B220+IgM- and B220+CD19- developmental stage 
(Fig. R4a, b).
Fig. R3.  c-Myc is required for B cell development.  (a) Total BM suspensions of c-mycfl/fl; mb--1cre/+ mice 
and control littermates were stained with antibodies to B220, IgM and CD43 to characterise immature B cell 
populations	by	flow	cytometry.	 	(b)	Absolute	numbers	of	B	lymphocytes	in	BM	of	c-mycfl/+; mb-1cre/+(black 
bars; n = 8) and c-mycfl/fl; mb-1cre/+ (open bars; n = 8).  P-value *** p<0.001.  (c) Representative BM staining 
with antibodies to B220, IgM and CD19 to study B lymphocytes in homozygous c-mycfl/fl;-mb-1cre/+; rosa26gfp/
gfp mice and control littermates.  GFP-positive cells were gated and analysed for surface expression of B220, 
IgM	and	CD19	to	define	the	different	cell	subsets:	B220+IgM- (pro- and pre-B cells), B220loIgM+ (immature 
B cells), B220hiIgM+ (mature B cells), and B220+CD19+ (pro-B cells).  (d) (left) Staining of spleen cells from 
c-mycfl/fl; mb-1cre/+; rosa26gfp/gfp (black bars) and littermate controls (grey bars).  GFP-positive cells were gated 
and studied for the surface expression of B220 and IgM, to study B220+IgM+ cells in the spleens of these mice. 
(right) Absolute numbers of spleen B220+IgM+ cells from c-mycfl/fl; mb-1cre/+; rosa26gfp/gfp (n=5) and control 
littermates (n=5) (e) Genomic PCR of sorted B220+IgM-GFP+ BM cells and B220+IgM+GFP+ cells from c-mycfl/
fl; mb-1cre/+; rosa26gfp/gfp mice and control littermates. (f) (left) Representative staining of BM cells from pIpC-
treated c-mycfl/fl; mx-cre+ mice and control littermates.  (right) Absolute numbers of B lymphocytes in BM of 
c-mycfl/+; mx-cre+ (black bars; n = 8) and c-mycfl/fl; mx-cre+ mice (open bars; n = 8).  All data are representative 
of at least three independent experiments.
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These results indicate that c-Myc is required 
for B cell differentiation both in vivo and in vitro. 
They also suggest that the few mature B cells found 
in c-mycfl/fl; mb-1cre/+ and c-mycfl/fl; mb-1cre/+; rosa26gfp/
gfp mouse spleens are not generated in the absence of 
c-Myc.
The other animal model, the inducible c-mycfl/
fl;mx-cre+ mice, allowed us to study the c-Myc 
requirement at later stages of B cell development. 
We induced c-myc deletion with pIpC in the BM of 
5- to 8-week-old c-mycfl/fl; mx-cre+ mice.  Five days 
after	 the	 last	 injection,	 mice	 were	 sacrificed	 and	 B	
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Fig. R4.  Differentiation of c-Myc-
deficient cells in vitro.  (a) IgM+ cells 
from BM of c-mycfl/fl; mb-1cre/+mice and 
control littermates were depleted using 
magnetic beads.  Cells were cultured 
in IMDM medium supplemented with 
SCF, Flt3L and IL-7 and allowed to 
differentiate for three days.  After 
this period, cells were stained with 
antibodies to B220, IgM and CD19, 
and differentiation was assessed by 
flow	cytometry	analysis.	(b)	As	in	(a),	
using c-mycfl/fl; mb-1cre/+; rosa26gfp/gfp 
mice and age-matched controls.
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cell	 differentiation	 was	 studied	 by	 flow	 cytometry.	
We observed that homozygous cmycfl/fl; mx-cre+ mice 
had	an	acute	reduction	(>3.5-fold)	in	absolute	B	cell	
numbers, as well as a reduction in both B220+IgM- 
cells (Fractions A to D) and B220loIgM+ cells (Fraction 
E) compared to c-mycfl/fl; mxcre- controls (Fig. R3f).
Taken together, all these data suggest that the 
c-myc gene is required for B cell development.
4.2.2.  c-Myc-deficient immature B cells die by 
apoptosis
One of the most studied functions of c-Myc is its 
role	in	apoptosis.		The	first	observation	that	implicated	
c-Myc	 in	 apoptosis	 was	 in	 murine	 fibroblasts,	 in	
which c-myc overexpression in low serum conditions 
led to programmed cell death (Evan et al., 1992) 
(Hueber et al., 1997) (Thompson, 1998).  Several 
studies correlated deregulation of c-myc expression 
with apoptosis in a number of cell lines.  In human 
and murine B lymphomas, apoptosis induced through 
the BCR correlates with negative modulation of c-myc 
levels (Brunner T et al., 1995). In immature B cell lines 
, BCR engagement leads to a drop in c-Myc protein, 
eventually leading to apoptosis (Wu et al., 1996)
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Fig.R5.  c-Myc-deficient immature B cells die by apoptosis.  (a) Representative annexin V staining.  Four-week-
old c-mycfl/fl; mb-1cre/+	mouse	BM	suspensions	were	stained	with	antibodies	to	B220,	IgM,	c-kit	to	define	pro-B	
cells (B220+c-kit+IgM-) and CD25 for pre-B cells (B220+CD25+IgM-).  Cells were further stained with annexin V 
to detect apoptotic cells (annexin V+) within pro- and pre-B populations.  (b) Annexin V staining of BM cells from 
c-mycfl/fl; mx-cre+ mice and control littermates.  B220+IgM- (pro- and pre-B cells), B220loIgM+ (immature B cells) 
and B220hi IgM+ (mature B cells) populations were gated and analysed for annexin V-positive cells.
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fl; mb-1cre/+ could be attributed to three possible reasons: 
an	 increase	 in	 apoptosis	 levels	 of	 c-Myc-deficient	
B lymphocytes, a decrease in the proliferation of these 
cells, or a combination of both.  To determine whether 
c-Myc-deficient	B	lymphocytes	died	by	apoptosis,	we	
used annexin-V staining in pro- and pre-B cells from 
homozygous c-mycfl/fl; mb-1cre/+ and heterozygous 
c-mycfl/+; mb-1cre/+ littermate control mice.  B220+IgM- 
cells can be subdivided into pro-B cells (B220+IgM-
c-kit+) and pre-B cells (B220+IgM-CD25+).  Our data 
showed a slight increase in annexin-V positive cells in 
both	c-Myc-deficient	pro-B	(0.6%	vs.	1.6%;	2.6-fold	
increase) and pre-B cells (3.5% vs. 10.3%; 2.9-fold 
increase) (Fig. R5a).
Annexin-V staining also revealed an increase 
in the relative numbers of apoptotic B220loIgM- 
(14.0% vs. 35.9%) and B220loIgM+ (27.8% vs. 76.9%) 
cells in the BM of c-mycfl/fl; mx-cre+ mice compared 
to controls (Fig. R5b).  Consistent with previous 
observations in c-mycfl/fl; cd19cre/+ mice (de Alboran 
et al., 2001), B220hiIgM+ mature B lymphocytes from 
c-mycfl/fl; mx-cre+ mice (26.6% vs. 31.5%) survived in 
the absence of c-myc.
These data suggested that c-Myc is required 
for the survival of pro-, pre- and immature B cells and 
strengthen our hypothesis that c-Myc is required for B 
cell differentiation.
4.2.3.  B lymphocytes are able to proliferate in the 
absence of c-Myc
By regulating cell cycle genes, c-Myc 
promotes proliferation in many cell types, including 
B lymphocytes (Bernard and Eilers, 2006).  To study 
proliferation	 in	 c-Myc-deficient	 B	 lymphocytes,	 we	
performed in vivo BrdU incorporation analysis in 
homozygous c-mycfl/fl; mb-1cre/+ mice and heterozygous 
c-mycfl/+; mb-1cre/+ littermate controls.  We sorted 
the B220+IgM- population, stained cells with anti-
BrdU antibody and assessed proliferation by FACS 
analysis.		c-Myc-deficient	pro-	and	pre-B	lymphocytes	
showed decreased proliferation compared to the same 
population in WT mice (7.9% vs. 22.9%; 2.8-fold 
decrease) (Fig. R6a).  Again, similar results were 
observed in B220+IgM- lymphocytes (18% vs. 34%, 
1.8- fold decrease) from c-mycfl/fl; mx-cre+(Fig. R6b).
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Fig. R6.  B lymphocytes proliferate in the absence of c-Myc.  (a) Five- to 10-week-old animals received 
BrdU injections to measure B cell proliferation by BrdU incorporation.  B220+IgM- cells from homozygous 
and control mice were sorted and stained with an anti-BrdU antibody and PI to identify proliferating cells. 
(b) (left) Scheme showing the percentage of BrdU-positive cells in c-mycfl/+; mb-1cre/+(black bars, n = 5) and 
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These	 results	 show	 that	 c-Myc-deficient	pro-	
and pre-B lymphocytes are able to proliferate in the 
absence of c-myc.
4.2.4.  V(D)J recombination is impaired in c-Myc-
deficient B lymphocytes
B cell development in the BM takes place in 
successive stages during which the IgH V (variable), D 
(diversity) and J (joining) gene segments are rearranged 
in an ordered and sequential fashion. First D
H
-to-J
H
 
segments rearrange, which are followed by V
H
-to-DJ
H
 
rearrangements.  To determine whether the impaired 
B	 cell	 differentiation	 observed	 in	 c-Myc-deficient	
lymphocytes was characterised by defective V(D)J
 
recombination, we sorted B220+IgM- BM cells from 
homozygous c-mycfl/fl; mb-1cre/+ and control littermates. 
Genomic	 PCR	 with	 specific	 primers	 for	 rearranged	
D
H
-J
H, 
V
Hproximal
-DJ
H
 and V
Hdistal
-DJ
H
 segments showed 
that	in	the	case	of	c-Myc-deficient	B220+IgM- cells, all 
types of rearrangements were reduced compared with 
control cells (Fig. R7).  These results indicated that 
c-Myc-deficient	 pro-	 and	 pre-B	 cells	 have	 impaired	
V(D)J recombination.
4.3.  Gene expression profile in c-Myc-deficient B 
cells
We next wanted to identify a molecular 
mechanism that could explain the requirement of 
c-Myc for B cell differentiation in c-mycfl/fl; mb-1cre/+ 
mice.  We analysed expression of several B cell-
specific	 genes	 in	 sorted	 B220+IgM- cells from 
both homozygous c-mycfl/fl; mb-1cre/+ and control 
c-mycfl/+; mb-1cre/+ mice (Fig. R8a, b).  As predicted, 
c-myc expression was downregulated in pro- and pre-B 
cells from homozygous mice, as compared to WT 
levels   The expression levels of transcription factors 
E2A, EBF and Pax5 were considerably reduced in 
c-Myc-deficient	pro-	and	pre-B	cells	compared	to	WT	
cells (Fig R8a).  In the case of pax5, expression levels 
were reduced not only for this transcription factor, 
but also for its well-known target genes such as blnk, 
n-myc, Igα and Igβ (Nutt et al., 1998) (Fig. R8a).
As described above (introduction section 
1.4), the E2A/EBF/Pax5 transcription factor network 
is	 involved	 in	 the	 specification	 and	 commitment	 of	
B cell progenitors into the B lineage (Bartholdy and 
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Fig. R7.  V(D)J recombination is impaired in c-Myc-deficient B lymphocytes.  PCR analysis of IgH 
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rearranged segments.
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Matthias, 2004) (Medina et al., 2004); (Roessler and 
Grosschedl, 2006) (Fuxa and Skok, 2007).  Our results 
show	that	c-Myc-deficient	pro-	and	pre-B	cells	have	
downregulated expression of key transcription factors 
involved in the B cell differentiation program.
4.4.  c-Myc deficient pro-B cells express lower 
surface levels of CD19 and pre-BCR than WT 
cells
Pax5-/- pro-B cells lack CD19 expression (Nutt 
et al., 1997).  CD19 is a direct Pax5 target gene, and 
measurement of CD19 surface levels by FACS is a 
good tool for measurement of Pax5 activity (Nutt et 
al., 1998).
We stained total BM cells and used FACS to 
detect surface expression of CD19 in B220+IgM- cells 
from c-mycfl/fl; mb-1cre/+ mice, control littermates, 
and from rag1‑/‑ and Eµ-myc transgenic mice as 
additional controls (Fig. R9a).  rag1‑/‑ mice have a 
B cell block at the pro-B cell stage similar to that of 
the c-mycfl/fl; mb-1cre/+ mice, and Eµ-myc transgenic 
mice constitutively express a c-myc transgene under 
the control of the Ig heavy chain enhancer Eµ.  CD19 
surface	levels	were	greatly	reduced	in	c-Myc-deficient	
pro- and pre-B cells (7.2% vs. 68.4%; 9.5-fold 
reduction) compared to wild-type, as well as to rag1‑/‑ 
and Eµ-myc	transgenic	mice.		This	confirm	the	results	
obtained in the previous section, in which we found 
that CD19 transcriptional levels were downregulated 
in B220+IgM- cells from c-mycfl/fl; mb-1cre/+ mice 
compared to wild-type mice.
Pax5-deficient	pro-B	cells	do	not	express	 the	
pre-BCR on their surface (Thevenin et al., 1998), 
(Schebesta et al., 2002), as these cells do not express the 
signal-transducing molecules Igα and Igβ, components 
of the pre-BCR.  To study pre-BCR surface levels in 
c-Myc-deficient	 B	 cells,	 we	 used	 an	 antibody	 that	
recognises a conformational epitope on the surrogate 
light chain-Igµ complex of the pre-BCR, and stained 
cells from c-mycfl/fl; mb-1cre/+, control littermates, from 
rag1‑/‑ and Eµ-myc transgenic mice.  We found that 
c-Myc-deficient	 cells	 expressed	 lower	 surface	 levels	
of the pre-BCR (0.1% vs. 0.3%; 3-fold decrease) than 
control cells (Fig. R9b).
These	 results	 show	 that	 c-Myc-deficient	
B220+IgM- cells have lower surface expression levels 
of CD19 and pre-BCR. 
4.5.  c-Myc-deficient B cells do not give rise to other 
lineages when cultured with appropriate cytokines
When they are stimulated with appropriate 
cytokines,	 Pax5-deficient	 pro-B	 cells	 are	 able	 to	
differentiate in vitro into functional macrophages, 
osteoclasts, dendritic cells, granulocytes and natural 
killer cells (Nutt et al., 1999).  Ectopic expression 
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Fig. R8.  c-Myc function in B cell differentiation.  (a) B220+IgM- cells from c-mycfl/fl; mb-1cre/+ and 
littermate control mice were sorted, and we synthesised cDNA and used qRT-PCR to study the expression 
of	a	battery	of	B	cell-specific	genes.		Data	represent	at	least	three	independent	experiments.
49
                      Results
of C/EBPα and GATA factors strongly promote in 
vitro macrophage differentiation and myeloid colony 
formation of Pax5-/- pro-B cells (Heavey et al., 2003). 
In	 another	 study,	 Pax5-deficient	 B	 cell	 progenitors	
transfer	into	Rag2-deficient	mice	provided	long-term	
reconstitution of T cell development (Rolink et al., 
1999).
To	study	whether	c-Myc-deficient	B	cells	were	
able to give rise to different lineages in vitro, we sorted 
B220+CD43+ cells from c-mycfl/fl; mb-1cre/+ and control 
littermates and cultured them in methylcellulose-based 
media supplemented with cytokines and growth factors, 
and	quantified	colony-forming	cells	of	 the	erythroid,	
granulocyte/macrophage and B lineages.  We found 
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Fig. R9.  c-Myc-deficient pro- and pre-B cells express lower surface levels of CD19 and pre-BCR than 
WT cells and do not generate cells of other lineages when cultured with appropriate cytokines.  (a) 
Lower	CD19	expression	levels	in	c-Myc-deficient	B	cells.		BM	of	the	indicated	genotypes	was	analysed	by	
flow	 cytometry,	 and	CD19	 expression	 is	 displayed	 for	 pro-	 and	 pre-B	 cells	 (B220+IgM-).  (b) Analysis of 
pre-BCR expression.  Representative FACS analysis of pre-BCR surface expression are shown for rag1‑/‑, 
Eµ-c-myc, c-mycfl/+; mb-1cre/+ and c-mycfl/fl; mb-1cre/+ mice.  Rag1‑/‑ and Eµ-c-myc mice are shown as negative 
and positive controls, respectively.  (c) Methylcellulose colony assays.  The lymphoid, myeloid and erythroid 
colony forming-activity of B220+CD43+ BM cells from c-mycfl/+; mb-1cre/+ and c-mycfl/fl; mb-1cre/+ mice was 
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semisolid methylcellulose media.
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that	c-Myc-deficient	B	cells	only	gave	rise	to	cells	of	
the	B	lineage	and	were	three	times	less	efficient	than	
WT cells (Fig. R9c).  These data indicate that c-Myc-
deficient	 immature	B	 lymphocytes	 are	 committed	 to	
the B lineage and cannot give rise to cells of other 
haematopoietic lineages when cultured in vitro with 
appropriate cytokines.
4.6.  Ectopic expression of Pax5 in c-Myc-deficient 
B lymphocytes
To study whether Pax5 expression in c-Myc-
deficient	 cells	 was	 sufficient	 to	 rescue	 the	 block	 in	
B cell differentiation, we used the Ikneo/+ conditional 
mouse model that expresses the pax5 gene from the 
endogenous ikaros promoter (Souabni et al., 2002).
Fig. R10.  Generation of Ikneo/+; c-mycfl/fl; mb-1cre/+ and Ikneo/+; c-mycfl/fl; mx-cre+ mice.  (a) Insertion of a pax5 
minigene into the Ikaros locus.  The conditional Ikneo allele was generared by inserting human pax5 cDNA 
together	with	a	floxed	neomycin	(neo) resistance gene upstream of the translation start codon in Ikaros exon 
2.  Pax5 cDNA was linked via an IRES site to a GFP gene and the 3’ polyadenylation (pA) region of the rabbit 
β-globin gene.  Red arrowheads: loxP sites.  (b) Generation of Ikneo/+; c-mycfl/fl; mb-1cre/+ and Ikneo/+; c-mycfl/
fl; mx-cre+ mice.  Ikneo mice were bred with c-mycfl/fl; mb-1cre/+ or c-mycfl/fl; mx-cre+ to generate two different 
mouse	models	for	the	study	of	Pax5	expression	in	c-Myc-deficient	B	cells.
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4.6.1.  Generation of Ikneo/+; c-mycfl/fl; mb-1cre/+ and 
Ikneo/+; c-mycfl/fl; mx-cre+
The Ikaros (Ik) gene is widely expressed 
throughout the haematopoietic system, including HSC 
and their committed progenitors (Kelley et al., 1998). 
To study the effect of Pax5 on the development of 
all haematopoietic lineages, we used a heterozygous 
knock-in mouse carrying pax5 gene under the control 
of the Ikaros locus (Souabni et al., 2002).  The 
conditional Ikneo/+ mouse was constructed by inserting 
a pax5 mini-gene linked via an IRES sequence to a 
GFP	 gene,	 together	 with	 a	 floxed	 neomycin	 (neo) 
resistance gene, into the Ik locus (Fig. R10a).  When 
these	mice	are	bred	with	mice	bearing	a	stage-specific	
Cre recombinase gene, the neo resistance gene is 
deleted and there is expression of Pax5 and GFP.
To	 express	 Pax5	 in	 c-Myc-deficient	 cells,	
we bred Ikneo/+ mice with either c-mycfl/fl; mb-1cre/+ 
or c-mycfl/fl; mx-cre+ mice (Fig. R10b).  The F2 
generations generated homozygous Ikneo/+; c-mycfl/
fl; mb-1cre/+ and control Ikneo/+; c-mycfl/+; mb-1cre/+, or 
homozygous Ikneo/+; c-mycfl/fl; mx-cre+ and control 
Ikneo/+; c-mycfl/+; mx-cre+ mice.  We generated two 
mouse models that express pax5 in B lymphocytes, 
although the onset of expression differs between the two 
models.  In the case of Ikneo/+; c-mycfl/fl; mb-1cre/+ mice, 
Pax5	is	expressed	in	a	constitutive,	specific	manner	in	
c-Myc-deficient	pro-B	cells.	 	For	Pax5	expression	in	
Ikneo/+; c-mycfl/fl; mx-cre+ mice, Cre recombinase must 
be activated by pIpC; once Cre is activated, Pax5 is 
expressed from the early precursors in the BM to the 
more mature B cells in spleen.
4.6.2. Ectopic expression of Pax5 in Ikneo/+; c-mycfl/
fl; mb-1cre/+ mice does not rescue B cell 
differentiation
To determine whether Pax5 expression in 
c-Myc-deficient	pro-	and	pre-B	cells	could	rescue	the	
developmental block observed in c-mycfl/fl; mb-1cre/+ 
mice, we obtained total BM from Ikneo/+; c-mycfl/
fl; mb-1cre/+ and control Ikneo/; c-mycfl/+; mb-1cre/+ mice 
and stained cells with the B220, IgM, CD19 and 
CD43 surface markers to allow us to distinguish 
B cell subsets.  We used both young mice (2-3 weeks 
of age) and adult mice, which showed no substantial 
differences.  Pax5 expression in these cells was 
insufficient	 to	 overcome	 the	 developmental	 block;	
neither B220+IgM+ nor B220+CD43- cells were found in 
the BM of homozygous Ikneo/+; c-mycfl/fl; mb-1cre/+ mice 
(Fig.R11a).  In addition, we found the same reduction 
in the B220+CD19+ population as previously observed 
in c-mycfl/fl; mb-1cre/+ mice.  Absolute numbers also 
reflected	a	severe	reduction	in	B	cells	(B220+; 8-fold 
decrease) and in B220+IgM+ cells (4.8-fold decrease) 
compared to age-matched controls (Fig. R11b).  We 
also analysed CD19 surface levels in B220+IgM- cells 
from Ikneo/+; c-mycfl/fl; mb-1cre/+ and control littermates, 
and	found	pro-	and	pre-B	c-Myc-deficient	lymphocytes	
had reduced CD19 surface expression levels (79.5% 
vs. 13.0%: 6-fold decrease) (Fig. R11c).  These results 
indicate that Ikneo/+; c-mycfl/fl; mb -1cre/+ mice show the 
same developmental blockade as c-mycfl/fl; mb-1cre/+ 
mice.
IgM-depleted BM cells from c-mycfl/+; mb-1cre/+ 
mice, c-mycfl/fl; mb-1cre/+ mice and Ikneo/+; c-mycfl/
fl; mb-1cre/+ mice were in vitro cultured and differentiation 
was analysed at days 3 and 7 (see section 4.4).  We 
found that BM cells from neither c-mycfl/fl; mb-1cre/+ nor 
Ikneo/+; c-mycfl/fl; mb-1cre/+ mice gave rise to B220+IgM+ 
or B220+CD19+ in vitro (Fig. R12). These results 
show that BM cells from Ikneo/+; c-mycfl/fl; mb-1cre/+ 
mice cannot differentiate into IgM+ B cells in vitro, 
confirming	our	earlier	results	in	section	4.4.
4.6.3.  Transcriptional expression levels of pax5, 
ebf, e2a and c-myc in pro- and pre-B cells from 
Ikneo/+; cmycfl/fl; mb-1cre/+ mice
To test whether the failure to rescue B cell 
differentiation upon expression of pax5 in c-Myc-
deficient	B	cells	in	Ikneo/+; c-mycfl/fl; mb-1cre/+ mice was 
due	 to	 inefficient	Pax-5	expression	 in	 these	animals,	
we measured the transcription levels of pax5 and 
c-myc.  We also analysed the expression of the B cell-
specific	factors	ebf1 and e2a, to determine whether the 
blockade was due solely to pax5 and c-myc deficiency,	
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or if downregulation of ebf1 and e2a was also involved. 
B220+IgM- cells from control c-mycfl/+; mb-1cre/+ and 
homozygous c-mycfl/fl; mb-1cre/+ and Ikneo/+; c-mycfl/
fl; mb-1cre/+ mice were sorted and cDNA was synthesised 
for	 qRT-PCR	with	 specific	 primers	 for	 these	 genes..	
We found that transcriptional levels of c-myc, pax5, 
ebf1 and e2a were downregulated (by 90.2-, 2.5-, 
67.3-, and 143-fold, respectively) in B220+IgM- cells 
from homozygous Ikneo/+; c-mycfl/fl; mb-1cre/+ compared 
to c-mycfl/+; mb-1cre/+ mice (Fig. R13).
Overall, these data indicates that B220+IgM- cells 
from homozygous Ikneo/+; c-mycfl/fl; mb-1cre/+, are unable 
to express pax5 at wild-type levels upon activation of 
cre recombinase.  In addition, transcriptional levels 
of ebf and e2a remain downregulated compared to 
control cells.
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Fig. R11.  Impaired B lymphopoiesis in Ikneo/+; c-mycfl/fl; mb-1cre/+mice.  (a)	Representative	flow	cytometric	
analysis of surface expression of B220, IgM, CD19 and CD43 to study B cell development in c-mycfl/+; mb-1cre/+, 
c-mycfl/+; mb-1cre/+, Ikneo/+; c-mycfl/+; mb-1cre/+ and Ikneo/+; c-mycfl/fl; mb-1cre/+ mice.  (b) Absolute numbers of B cells 
(B220+) and pro- and pre-B cells (B220+IgM-) in the BM of mice of the genotypes in (a).  P <0.001.  (b) CD19 
surface expression in pro- and pre-B cells from the same genotypes as above.  Stainings are representative of 
at least three independent experiments.
53
                      Results
4.6.4.  In vivo rescue of B cell differentiation in 
Ikneo/+; c-mycfl/fl; mx-cre+ mice
To determine whether pax5 expression in early 
progenitors could rescue B lymphopoiesis in c-Myc-
deficient	mice,	we	used	4-	to	6-week-old	animals	that	
were inoculated three times with 150 µg pIpC and 
sacrificed	three	days	after	the	last	injection.		Cell	surface	
marker expression analysis (see section 4.7.2) showed 
substantial rescue when we compared the phenotype 
of Ikneo/+; c-mycfl/fl; mx-cre+ with homozygous c-mycfl/
fl; mx-cre+ knockout mice (Fig. R14a).  Examination of 
B220 vs. CD43 staining indicated that although relative 
B220+CD43+ cell numbers remained similar, there was 
an increase in the B220loCD43- population in Hardy 
Fractions D and E (3.1% vs. 0.8%; 3.9-fold increase). 
A similar increase was observed in the B220+IgM- 
population comprised by Fractions A to D (8.0% 
vs. 4.9%; 1.6-fold increase) and in the B220loIgM+ 
population, which corresponds to Fraction E (2.1% 
vs. 0.8%; 2.6-fold increase).  Comparison of absolute 
cell numbers between homozygous Ikneo/+; c-mycfl/
fl; mx-cre+ and c-mycfl/fl; mx-cre+ knockout mice (Fig.
R14b) reflected	a	more	acute	 increase	 in	B220+IgM- 
cells (1.7 x 106 vs. 0.7 x 106; 2.4-fold increase) and in 
B220loIgM+ (0.5 x 106 vs. 0.1 x 106; 5-fold increase). 
These results suggest that ectopic Pax5 expression in 
c-Myc-deficient	BM	from	haematopoietic	precursors	
enables rescue of B cell differentiation in vivo.
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Fig. R12.  BM cells from Ikneo/+; c-mycfl/fl; mb-1cre/+ mice cannot differentiate into IgM+ cells in vitro.  Cells 
were	cultured	as	described	(see	Materials	and	Methods)	and	analysed	by	flow	cytometry	at	days	3	and	7	of	
culture for B220, IgM and CD19 expression.
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Fig. R13.  Transcriptional levels of pax5, ebf, 
e2a and c-myc in pro- and pre-B cells from 
Ikneo/+; c-mycfl/fl; mb-1cre/+ mice.  B220+IgM- 
cells from Ikneo/+; c-mycfl/fl; mb-1cre/+ mice and 
cmycfl/+; mb-1cre/+ controls were sorted; we then 
synthesised cDNA and used qRT-PCR to study the 
expression of Pax5, EBF and E2A transcription 
factors.
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We also analysed CD19 surface expression 
in B220+IgM-, B220loIgM+ and B220hiIgM+ cells to 
assess Pax5 activity (Fig. R14c).  B220+IgM- cells 
from Ikneo/+; c-mycfl/fl; mx-cre+ mice rescued CD19 
expression as compared to homozygous c-mycfl/
fl; mx-cre+ mice, whereas we found no differences in the 
three mouse genotypes in surface CD19 expression on 
B220loIgM+ and B220hiIgM+ cells.  This concurs with 
our prediction, as CD19 expression begins in fraction B 
and remains throughout development until the mature 
B cell stage (Nagasawa, 2006).  The increase in surface 
CD19 expression on B220+IgM- cells in Ikneo/+; c-mycfl/
fl; mx-cre+ compared to c-mycfl/fl; mx-cre+ mice was also 
reflected	by	absolute	cell	numbers	 (1.0	x	106 vs. 0.3 
x 106;	3.3-fold	increase)	(Fig.	R14d).		These	findings	
indicate	that	Pax5	expression	in	c-Myc-deficient	pro-	
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Fig. R14.  In vivo rescue of B cell differentiation in Ikneo/+; c-mycfl/fl; mx-cre+ mice.  (a) BM cells from 4- to 
6-week-old pIpC-inoculated mice of the indicated genotypes were stained with the antibodies indicated in Fig. 
R12 to study B cell development.  (b) Absolute numbers of B220+IgM- (pro- and pre-B cells), B220loIgM+ 
(immature B cells) and B220hiIgM+ (mature B cells) from control c--mycfl/fl; mx-cre- (n = 4), homozygous 
c-mycfl/fl; mx-cre+(n = 4) and Ikneo/+; c-mycfl/fl; mx-cre+(n = 5) mice.  (c) CD19 expression in the different B 
cell subsets.  CD19 expression is displayed for B220+IgM-, B220loIgM+ and B220hiIgM+ cells.  (d) Absolute 
numbers of CD19+ cells in the different B cell subpopulations from c-mycfl/fl; mx-cre- (n=3), c-mycfl/fl; mx-cre+ 
(n = 3) and Ikneo/+; c-mycfl/fl; mx-cre+(n = 4) mice.
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and	pre-B	 lymphocytes	 is	 sufficient	 to	 induce	CD19	
surface expression in these cells.
4.6.5.  c-Myc-deficient B cells from Ikneo/+; c-mycfl/
fl; mx-cre+ mice can differentiate into IgM+ B cells 
in vitro
To study whether Pax5 expression induced not 
only	survival	of	c-Myc-deficient	B	lymphocytes,	but	
also B cell differentiation, we depleted IgM-positive 
cells from BM (see section 4.4).  Young adult (4- to 
6-week-old) mice were inoculated three times with 
400 µg	pIpC	and	sacrificed	three	days	after	the	last	dose.	
We cultured IgM-depleted BM from c-mycfl/fl; mx-cre-, 
from c-mycfl/fl; mx-cre+, from Ikneo/+; c-mycfl/fl; mx-cre- 
and from Ikneo/+; c--mycfl/fl; mx-cre+ mice for 3 days and 
evaluated IgM+	cells	by	FACS	analysis.		We	identified	
B220+IgM+ cells in homozygous Ikneo/+; c-mycfl/
fl; mx-cre+ mice, whereas no cells of this type were 
generated in homozygous c-mycfl/fl; mx-cre+ mice (Fig. 
R15a).  Finally, Ikneo/+; c-mycfl/fl; mx-cre+ mice were 
able to generate B220+CD19+ cells, which were not 
present in c-mycfl/fl; mx-cre+ mice (Fig. R15a).  These 
results show that pax5	expression	in	c-Myc-deficient	
B cells from Ikneo/+; c-mycfl/fl; mx-cre+	mice	is	sufficient	
to overcome the B cell differentiation impairment in 
vitro and suggests that it does so in vivo too.
4.6.6.  Transcriptional expression levels of pax5, 
ebf, e2a and c-myc in immature B cells from 
Ikneo/+; c-mycfl/fl; mx-cre+ mice
To analyze the transcriptional levels of the 
pax5, ebf, e2a and c-myc genes, we sorted B220+IgM- 
cells from pIpC-treated control c-mycfl/fl; mx-cre-, 
homozygous Ikneo/+; c-mycfl/fl; mx-cre+ and c-mycfl/
fl; mx-cre+ mice.  We synthesised cDNA and used qRT-
PCR to study pax5, ebf, e2a and c-myc expression. 
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Fig. R15.  In vitro rescue of B cell differentiation in Ikneo/+; c-mycfl/fl; mx-cre+ mice.  (a) BM cells of the 
indicated genotypes were cultured in vitro and	differentiation	was	 analysed	by	flow	cytometry	 at	 day	3	of	
culture for B220, IgM and CD19 expression.  (b) Absolute numbers of B220+IgM- and B220+IgM+ cells at day 
3 of culture for the indicated genotypes.
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Comparison of Ikneo/+; c-mycfl/fl; mx-cre+ and c-mycfl/
fl; mx-cre mice showed upregulation of pax5 and e2a 
transcriptional levels by 2.9- and 4.7-fold, respectively, 
whereas no substantial differences were found for 
c-myc and ebf1.  When we compared the levels for 
these genes in B220+IgM- cells from Ikneo/+; c-mycfl/
fl; mx-cre+ and homozygous c-mycfl/fl; mx-cre+ mice, we 
found upregulated transcription for pax5, ebf1 and e2a 
(4.0-, 2.9-, and 8.6- fold, respectively) (Fig. R16a). 
These data suggest that ectopic Pax5 expression in 
pro- and pre-B cells from Ikneo/+; c-mycfl/fl; mx-cre+ is 
able to restore the transcriptional program of the E2A/
EBF/Pax5 network of transcription factors.
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Fig. R16.  Transcriptional levels of pax5, ebf, e2a and c-myc in pro- and pre-B cells from Ikneo/+; c-mycfl/
fl; mx-cre+ mice.  B220+IgM- cells from Ikneo/+; c-mycfl/fl; mx-cre+ mice, c-mycfl/fl; mx-cre- mice and c-mycfl/
fl; mx-cre+mice were sorted; we then synthesised cDNA and used qRT-PCR to study the expression of Pax5, 
EBF and E2A transcription factors.  (a) Comparison of transcriptional levels between cells from Ikneo/+; c-mycfl/
fl; mx-cre+ and c-mycfl/fl; mx-cre- mice.  (b) Comparison of transcriptional levels between cells from Ikneo/+; c-mycfl/
fl; mx-cre+ and c-mycfl/fl; mx-cre+mice.
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5. Discussion
In this study, we provide insight into the role 
of the proto-oncogene c-myc in B lymphopoiesis. 
Using conditional mouse models bred with distinct 
stage-specific	Cre recombinase strains, we show an 
essential function for c-Myc in B cell development. 
We	identified	several	genes	that,	together	with	c-Myc,	
might contribute to this developmental process.  To 
test our hypothesis, we performed gain-of-function 
studies that demonstrate that c-Myc regulates the 
expression of key transcription factors involved in the 
specification	and	commitment	of	lymphoid	precursors	
towards the B cell lineage.
The use of two mouse models that inactivate 
c-myc at different time points has allowed us to 
establish a new mechanism of c-Myc function in 
B	 cell	 development.	 	 In	 the	 first	 model,	 c-mycfl/
fl; mb-1cre/+ inactivates c-myc in a constitutive fashion 
specifically	 in	cells	of	 the	B	 lineage,	allowing	study	
of	 B	 lymphopoiesis	 in	 c-Myc-deficient	 immature	 B	
cells.  In the second model, c-mycfl/fl; mx-cre+ (Baena 
et al., 2005), inactivation of c-myc is under the control 
of an inducible promoter (mx1).  This results in c-myc 
deletion	 in	several	organs,	with	highest	efficiency	 in	
liver and BM.  These mice inactivate c-myc starting at 
the HSC stage, (Baena et al., 2007) and are therefore an 
appropriate tool with which to study B lymphopoiesis 
from	c-Myc-deficient	haematopoietic	precursors.
To study B cell development in the BM of these 
mice, we analyzed a variety of cell surface markers 
that	 define	 immature	B	 cell	 subsets.	 	 In	 the	 case	 of	
c-mycfl/fl; mb-1cre/+ mice, we found a blockade in the 
B cell developmental process and detected only cells 
of the B220+IgM- and B220+CD43+ phenotype.  The 
absolute numbers of B220+ and B220+IgM- cells were 
also reduced by two- and three-fold, respectively.  In 
the case of c-mycfl/fl; mx-cre+, there was a reduction in 
both the relative and absolute numbers of the immature 
B	 cell	 subpopulations	 defined	 by	 B220+IgM- and 
B220loIgM+cells.  The data generated in both mouse 
models suggest a requirement for the c-myc proto-
oncogene in B cell development.  In c-mycfl/fl; mb-1cre/+ 
mice, c-myc inactivation begins at the pro-B cell stage; 
pro-B	cells	are	consequently	c-Myc-deficient,	but	the	
pool of precursors that give rise to B cells are wild-type 
cells.   In contrast, in c-mycfl/fl; mx-cre+ mice, c-myc is 
deleted from the earliest progenitors in the BM, i.e., 
BM	precursor	cells,	and	give	rise	to	c-Myc-deficient	
B lymphocytes.
In c-mycfl/fl; mb-1cre/+; ROSA26-egfp mouse 
spleen, we detected some B220hiIgM+ cells, although 
many fewer than in wild-type mice (16.8-fold 
decrease).  To determine whether the block in the B 
cell	 differentiation	 process	 of	 c-Myc-deficient	 cells	
was due entirely to c-myc inactivation, we cultured 
IgM-depleted B lymphocytes in vitro with appropriate 
cytokines to allow B lymphocyte expansion.  Our 
findings	 demonstrate	 that	 c-Myc-deficient	 BM	 cells	
cannot give raise to IgM-expressing mature B cells, 
either in vivo or in vitro.  These experiments clearly 
demonstrate that the B cell developmental blockade 
is	an	intrinsic	failure	of	c-Myc-deficient	immature	B	
lymphocytes, and that the mature B cells found in the 
spleens of these mice are not generated in the absence 
of	c-Myc.		These	data	concur	with	our	previous	finding	
that pro-, pre- and immature B cells die by apoptosis 
due to c-myc inactivation.
The process of B cell differentiation comprises 
a series of proliferation, apoptosis and differentiation 
steps from early committed precursors to mature B 
cells;	these	steps	are	regulated	by	lineage-specific	and	
non-specific	genes.		Of	the	various	biological	in vivo 
functions of c-Myc, induction of apoptosis and cell 
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proliferation are currently the best characterised.  As 
several studies have correlated c-Myc expression with 
apoptosis in various cell lines, we analysed apoptosis in 
c-Myc-deficient	B	lymphocytes.		We	obtained	similar	
results in c-mycfl/fl; mb-1cre/+ and c-mycfl/fl; mx-cre+ mice. 
c-Myc-deficient	 immature	 B	 lymphocytes	 (pro-	 and	
pre-B) from c-mycfl/fl; mb-1cre/+ mice showed increased 
apoptosis compared to wild-type cells.  In c-mycfl/
fl; mx-cre+ mice, we observed an increase in the relative 
numbers of apoptotic B220loIgM- and B220loIgM+ cells 
in the BM of homozygous mice compared to wild-type 
control cells.  These results suggest that when cells 
inactivate c-myc, they die by apoptosis.  Attempts to 
rescue	the	survival	of	c-Myc-deficient	B	lymphocytes	
were previously tried in our lab by breeding c-mycfl/
fl; mx-cre+ mice with Bcl-2 transgenic mice, which 
overexpress the potent Bcl-2 anti-apoptotic protein. 
The	 resulting	mice	express	Bcl-2	 in	c-Myc-deficient	
BM cells.  However, experiments carried out with 
these mice showed that Bcl-2 did not inhibit cell death 
of B lymphocytes.  When we studied proliferation of 
immature B lymphocytes, we found that immature 
B cells (pro- and pre-B) were able to proliferate in 
the absence of c-Myc, although at a lower rate that 
wild-type cells.  This led to the hypothesis that at this 
developmental stage, B cell proliferation is a c-Myc-
independent event or that other genes, of the Myc 
family or for other transcription factors, compensate 
the c-Myc defect.  These data suggest that c-myc is not 
essential for pro- and pre-B cell proliferation, but could 
compromise optimal proliferation of these cells.
Gene	 expression	 analysis	 in	 c-Myc-deficient	
pro- and pre-B cells showed that the levels of several 
transcription factors known to be key regulators 
of	 B	 lineage	 specification	 and	 commitment	 were	
downregulated in these cells.  Transcription levels 
of tcfe2a (which codes for the E2A protein) and ebf1 
(which encodes EBF) were downregulated in c-Myc-
deficient	 cells	 by	 6.9-	 and	 2.3-fold,	 respectively,	
compared to wild-type cells.  These transcription factors 
are important regulators at the earliest stages of B cell 
differentiation, from common lymphoid progenitors 
to pro-B cells (Bartholdy and Matthias, 2004; Medina 
et al., 2004).  Moreover, pax5 transcription levels 
were	 downregulated	 by	 17-fold	 in	 c-Myc-deficient	
B220+IgM- cells. The Pax5 transcription factor plays 
an important role in commitment and the maintenance 
of B cell identity (Fuxa and Skok, 2007).  In addition, 
Pax5	 regulates	 the	 expression	 of	 B	 lineage-specific	
genes such as blnk, N-myc and cd79a, which were 
also	downregulated	in	c-Myc-deficient	pro-	and	pre-B	
cells.	 	 Our	 findings	 suggest	 that	 the	 differentiation	
block caused by c-myc inactivation is caused by the 
regulation of potential downstream Myc targets such 
as E2A, EBF and Pax5.
Knock-out mouse models have been 
generated for E2A, EBF and Pax5, and have shown 
that absence of these proteins leads to blockages in 
B cell differentiation, either at the onset of B lineage 
commitment or at the beginning of V
H
-to-DJ
H
 
recombination.	 	E2A-	 and	EBF-deficient	mice	 show	
a developmental block at the pre-pro-B cell stage (or 
Fraction A) and fail to rearrange D
H
-to-J
H
 segments 
(Bain et al., 1994; Lin and Grosschedl, 1995).  The 
Pax5-deficient	 mice	 show	 a	 developmental	 block	
at the pro-B cell stage, with impaired V
H distal
-to-DJ
H
 
recombination (Nutt et al., 1997; Urbanek et al., 1994). 
We analysed the rearrangement status of the IgH chain 
in	 c-Myc-deficient	 pro-	 and	 pre-B	 cells	 and	 found	
impaired rearrangements for D
H
-to-J
H
, V
H proximal
-to-DJ
H
 
and V
H distal
-to-DJ
H 
segments.  c-myc inactivation in 
pro- and pre-B cells therefore causes defective Ig 
heavy chain rearrangement.   We nonetheless cannot 
conclude whether this impairment is caused by the 
downregulated E2A, EBF and/or Pax5 transcription 
factor levels or that it is likely that the impairment in 
V(D)J recombination is a secondary effect.
CD19 expression is considered the hallmark of 
B cell commitment by B cell precursors, and is also 
a direct target gene of the Pax5 transcription factor. 
CD19 expression begins at the pro-B cell stage and its 
expression is maintained up to the mature B cell stage. 
We found greatly reduced CD19 expression levels 
in	 pro-	 and	 pre-B	 cells	 from	 c-Myc-deficient	 bone	
marrow.  Analysis of cell surface CD19 levels Hardy 
fractions A, B, C and C’ from wild-type and c-mycfl/
fl; mb-1cre/+	mice	confirmed	a	notable	reduction	in	this	
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protein in mutant mouse fraction B, which corresponds 
to the onset of CD19 expression.  Expression of pre-
BCR acts as an important developmental checkpoint 
by controlling the pro- to pre-B cell transition.  The 
pre-BCR is a complex formed by Igµ, the surrogate 
light chains λ5 and VpreB, and the signal-transducing 
proteins Igα and Igβ.		Mice	deficient	in	E2A,	EBF	or	
Pax5 fail to express the pre-BCR on the surface of large 
pre-B cells, due to downregulated expression of genes 
that encode one or more of the pre-BCR components. 
c-Myc-deficient	 B	 cells	 expressed	 lower	 pre-BCR	
levels	on	their	surfaces.		These	findings	further	support	
the hypothesis that downregulation of EBF and Pax5 
levels account for the B cell differentiation blockade 
in	c-Myc-deficient	B	cells.
Another	characteristic	feature	of	Pax5-deficient	
B cells is that they are uncommitted progenitors that 
can give rise to other haematopoietic lineages, both 
in vivo and in vitro (Nutt et al., 1999; Rolink et al., 
1999).  We tested the in vitro plasticity of c-Myc 
deficient	 pro-B	 cells	 from	 c-mycfl/fl; mb-1cre/+ mice. 
These cells did not generate myeloid nor erythroid 
lineage cells; they generated only B lineage cells and 
less	efficiently	than	wild-type	cells.		The	few	colonies 
obtained in the case of colony-forming erythrocytes 
and granulocytes/macrophages were considered to 
be background levels, as in similar assays wild-type 
BM progenitors normally give rise to larger numbers 
of	colonies	(25-150	colonies	per	dish).		Our	findings	
suggest	that	c-Myc-deficient	pro-B	cells	are	B	lineage-
committed cells that cannot progress to more mature 
B cell differentiation stages because they die due to 
c-myc inactivation.
To determine whether Pax5 downregulation 
cooperated with c-Myc in the impairment in B cell 
differentiation	observed	 in	c-Myc-deficient	mice,	we	
performed gain-of-function studies for Pax5.  We 
used a conditional mouse model in which Pax5 is 
overexpressed in distinct cells of the haematopoietic 
lineage cells, depending on the breeding of Ikneo/+ 
mice	 with	 mice	 bearing	 different	 stage-specific	Cre 
recombinase genes.  Two mouse models expressing 
Pax5	 in	 c-Myc-deficient	 BM	 cells	 were	 generated,	
one	with	 specific	 Pax5	 expression	 in	 the	 pro-B	 cell	
subpopulation (Ikneo/+; c-mycfl/fl; mb-1cre/+) and the other 
in which expression began in early haematopoietic 
precursors (Ikneo/+; c-mycfl/fl; mx-cre+).  Our attempts to 
rescue B cell development by generating Ikneo/+; c-mycfl/
fl; mb-1cre/+ were unsuccessful.  Cells were unable to 
progress beyond the B220+IgM- or B220+CD43+ stages 
of differentiation, and also showed acute reduction in 
relative numbers of the B220+CD19+ subpopulation. 
On the contrary, Ikneo/+; c-mycfl/fl; mx-cre+ mice showed 
an increase in both relative and absolute numbers of 
B220+IgM- and B220loIgM+ subpopulations compared 
to c-mycfl/fl; mx-cre+ mice (2.4- and 5-fold increase in 
absolute numbers, respectively).  Relative numbers of 
the B220loCD43- subpopulation (Hardy fraction E or 
small pre-B cells) also showed a substantial increase 
(3.1% vs. 0.8%, 3.9-fold increase) compared to the 
same population in c-mycfl/fl; mx-cre+ mice.  The 
differences between the two mouse models could 
be attributed to the timing of Pax5 expression and 
of c-myc inactivation. In the case of Ikneo/+; c-mycfl/
fl; mb-1cre/+mice, the inability to overcome c-Myc 
deficiency	might	be	caused	by	the	brief	time	window	
available for Pax5 expression before cells die due to 
c-myc deletion, whereas in Ikneo/+; c-mycfl/fl; mx-cre+ 
mice, Pax5 might be expressed before the cell 
inactivates c-myc, allowing the cell to proceed through 
the B cell differentiation program.
IgM-depleted BM cells were cultured and 
expanded in vitro in B lineage conditions to determine 
whether these conditions could rescue cells from the 
developmental block and generate IgM-positive cells 
in vitro in Ikneo/+; c-mycfl/fl; mb-1cre/+ and Ikneo/+; c-mycfl/
fl; mx-cre+ mice.  In the case of Ikneo/+; c-mycfl/
fl; mb-1cre/+ mice, BM and pro-B cells generated 
neither IgM-positive cells nor B220+CD19+ cells 
in vitro.  Not only was the ability to generate IgM-
positive cells reduced, but the capacity to produce B 
lineage cells was also diminished at culture day 3. 
Ikneo/+; c-mycfl/fl; mb-1cre/+ BM cells, thus showed no 
obvious differences relative to c-mycfl/fl; mb-1cre/+ cells. 
Surprisingly,	 Pax5-expressing	 c-Myc-deficient	 BM	
cells from Ikneo/+; c-mycfl/fl; mx-cre+ mice generated 
IgM-positive cells after 3 days in culture, while cells 
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from c-mycfl/fl; mx-cre+ mice did not (9.3% vs. 0.6%; 
15.5-fold increase); absolute numbers these cells were 
also increased in Ikneo/+; c-mycfl/fl; mx-cre+ mice.  In 
addition, Pax5-expressing cells from Ikneo/+; c-mycfl/
fl; mx-cre+ mice showed a restored capacity to generate 
B220+CD19+	cells	compared	to	c-Myc-deficient	cells	
from c-mycfl/fl; mx-cre+ mice (31.2% vs. 8.2%; 3.8-
fold	 increase).	 	 Our	 experimental	 findings	 suggest	
that	 whereas	 Pax5	 expression	 in	 c-Myc-deficient	
haematopoietic precursors is able to restore the 
capacity of these cells to progress through the B cell 
developmental	pathway,	it	is	insufficient	to	confer	this	
advantage	when	 expressed	 in	 c-Myc-deficient	 pro-B	
cells.
Our results suggest that c-Myc could be 
modulating cell fate by direct or indirect regulation 
of transcription factors involved in lineage cell 
commitment.  Regarding B and T lymphocytes, c-Myc 
is expressed in both cell types (Douglas et al., 2001) 
and is necessary for the differentiation of both B and 
T	 lymphocytes.	 	 c-Myc-deficient	T	 lymphocytes	 are	
blocked at the DN stage of development and fail to 
undergo further differentiation into DP cells (Douglas et 
al., 2001).  It is not known at which exact developmental 
stage the T versus B cell lineage commitment takes 
place, but it is thought that low Notch1 activity is 
sufficient	 to	 inhibit	 B	 cell	 differentiation,	 whereas	
higher	Notch1	activity	might	be	sufficient	to	drive	T	
cell differentiation (Schmitt et al., 2004; Tan et al., 
2005).  Overall, one possibility could be that c-Myc 
might reinforce the cell fate decision once the cell has 
already committed to either the B or T lineage. 
Our results show that, when expressed by 
early precursors in the BM, Pax5 rescues B cell 
development	 by	 c-Myc-deficient	 lymphocytes.	
Pax5 and EBF are key transcription factors in B cell 
specification	and	commitment,	and	Pax5 transcription 
is induced by Ebf1 (Medina et al., 2004; O’Riordan 
and Grosschedl, 1999).  Pax5 expression is needed 
to maintain commitment to the B lineage, which is 
achieved in part by the creation of a feedback loop that 
sustains EBF expression throughout the life of a B cell 
(Roessler et al., 2007).  Experiments should be carried 
out to test EBF transcriptional levels in rescued Pax5-
expressing	c-Myc-deficient	B	cells.	 	It	remains	to	be	
determined whether EBF expression or restoration of 
E2A	expression	in	c-Myc-deficient	BM	cells	would	be	
sufficient	to	rescue	B	cell	differentiation	by	“switching	
on” the B cell developmental program.  Based on 
our	 findings,	 we	 hypothesize	 a	 model	 in	 which	
c-Myc could regulate the E2A-EBF-Pax5 network 
of transcription factors, which have crucial roles at 
E2A EBF PAX5
CLP Pro-B
Pre-BCR
Large
pre-B
Small
pre-B
Immature B
BCR
c-Myc
??
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Pre-BCR
Figure D1. Proposed mechanism for the role of the proto-oncogene c-myc in the control of B cell 
development.  Dashed lines represent open questions.  The parallel blue lines represent the developmental 
block observed in c-mycfl/fl; mb1cre/+ mice, and blue arrows indicate the reduction in the numbers of the 
distinct B cell populations observed in c-mycfl/fl; mx-cre+ mice.
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the onset of B cell development.  The mechanism by 
which c-Myc controls B cell differentiation could be 
clinically relevant for c-Myc-induced tumours such 
as	Burkitt’s	lymphoma	and	leukaemia.		Identification	
of Myc target genes is of extreme importance, given 
their potential as therapeutic targets in the treatment of 
these	human	cancers.		To	integrate	these	findings	into	
a model (Fig. D1), we speculate that the c-myc proto-
oncogene controls the B cell differentiation program 
by regulating the expression of transcription factors 
involved in B cell commitment (such as Pax5 and 
probably	EBF),	and	in	turn	influencing	the	survival	of	
pro-, pre- and immature B cells.

    Conclusions

Conclusions
69
6. Conclusions
1.  c-myc is necessary for the survival and maintenance of pro-B, pre-B and immature B lymphocytes.
2.  Pro-B, pre-B and immature B lymphocytes are able to proliferate in the absence of  c-myc.
3.  Inactivation of c-myc in pro-B and pre-B cells results in impaired V(D)J recombination in c-mycfl/fl; mb-1cre/+ 
mice.
4.		Gene	expression	levels	of	the	E2A,	EBF	and	Pax5	transcription	factors	are	downregulated	in	c-Myc-deficient	
B220+IgM- cells from c-mycfl/fl; mb-1cre/+ mice.
5.		c-Myc-deficient	pro-B	and	pre-B	lymphocytes	have	reduced	cell	surface	expression	levels	of	CD19	and	pre-
BCR.
6.  Ectopic Pax5 expression from the Ikaros endogenous locus is able to promote B cell differentiation from 
B220+IgM- to B220loIgM+ cells in vitro in Ikneo/+; c-mycfl/fl; mx-cre+ mice.
7.  Ectopic Pax5 expression in pro- and pre-B cells from Ikneo/+; c-mycfl/fl; mx-cre+ is able to restore the transcriptional 
program of the E2A/EBF/Pax5 network of transcription factors.
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7.1. Introducción
Las proteínas Myc (N-, L- y c-) son miembros 
de la familia de factores de transcripción “basic/
helix-loop-helix/leucine zipper”, implicadas en la 
regulación de la proliferación celular, tamaño celular, 
diferenciación y apoptosis (Askew et al., 1991; Evan 
et al., 1992; Facchini LM and LZ, 1998; Henriksson 
and Luscher, 1996; Kelly et al., 1983; Waters et al., 
1991; Wisden et al., 1990).  La expresión de c-myc 
es ubícua y está modulada a lo largo del ciclo celular. 
Así, la estimulación mitógenica de células quiescentes 
incrementa  la expresión de c-myc a niveles 
máximos en la transición G0/G1 a S, disminuyendo 
progresivamente a lo largo del ciclo celular (Campisi 
et al., 1984; Kelly et al., 1983).  La desregulación de la 
expresión de c-myc está implicada en el desarrollo de 
distintas patologías, tanto en  ratón como en humanos, 
tal como linfoma de Burkitt, cáncer de mama o de 
pulmón (Adams and Cory, 1985; Dalla-Favera et al., 
1982; Leder et al., 1986; Morgenbesser and DePinho, 
1994; Spanopoulou E et al., 1989).  Sólo en Estados 
Unidos, se estima que la frecuencia de alteraciones 
genéticas de c-myc, en cánceres humanos, causa del 
orden de 100.000 muertes al año. 
 Las evidencias experimentales que implican a 
c-myc en procesos proliferativos y apoptóticos están 
basadas, abrumadoramente, en líneas celulares.  La 
expresión ectópica de c-myc en células quiescentes 
induce la entrada en la fase S del ciclo celular y acorta 
su duración en diferentes tipos celulares (Eilers et 
al., 1991; Palmieri S et al., 1983; Stern DF, 1986). 
Tanto su capacidad para promover la entrada en el 
ciclo celular, como su regulación durante el mismo, 
llevaron a pensar que c-Myc podría estar modulando 
genes responsables del control  del ciclo.  Así, multitud 
de datos experimentales indican que c-myc induce la 
proliferación celular activando genes reguladores 
positivos del ciclo celular (Mateyak et al., 1997; 
Zornig and Evan, 1996) como de ciclina d1, d2 , e, a 
y cdc25A, o reprimiendo inhibidores del ciclo celular 
como p21 y p27 (Bouchard et al., 1999; Daksis JI, 
1994; Galaktionov et al., 1996; Hoang AT et al., 1994). 
Otra de las funciones más estudiadas de c-Myc es la 
apoptosis.  La primera prueba de la implicación de 
c-Myc	en	apoptosis,	se	observó	en	fibroblastos	cuando	
la sobreexpresión de c-myc, en condiciones limitantes 
de suero, provocaba muerte celular programada de 
los mismos (Askew et al., 1991; Evan et al., 1992; 
(Thompson et al., 1998).  A raíz de estos resultados, 
surgieron multitud de estudios que correlacionaban 
una modulación positiva o negativa de la expresión de 
c-myc con apoptosis en diferentes tipos celulares.                      
En el caso de linfomas B humanos y murinos, la 
apoptosis inducida a través del receptor de la células B 
(BCR) correlaciona con una modulación negativa de 
la expresión de c-myc (Brunner T et al., 1995; Dhein J 
et al., 1995; Ju ST et al., 1995).  En contraste con estos 
resultados, se ha demostrado que linfocitos primarios 
B	deficientes	en	c-Myc	tienen	una	mayor	resistencia	
a la muerte inducida a través de CD95-CD95L o a 
la muerte espontánea en cultivo (de Alboran et al., 
2004).  En líneas generales, todos estos trabajos 
parecen indicar que la función de c-Myc en apoptosis, 
proliferación o diferenciación no sólo depende del tipo 
celular sino del estadío de diferenciación en el cual se 
encuentra la célula. 
c-Myc se expresa durante todos los estadíos 
de diferenciación de los linfocitos B (Morrow et al., 
1992; Zimmerman and Alt, 1990) .  Los linfocitos B 
son generados a partir de los progenitores pluripotentes 
por un proceso altamente controlado que tiene lugar 
en el hígado fetal, y en la médula ósea y los órganos 
linfoides secundarios, en la fase adulta .  El proceso 
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de desarrollo de los linfocitos B, está íntimamente 
ligado al reordenamiento de las cadenas pesada y 
ligera de las inmunoglobulinas.  El primer estadío 
de diferenciación, se conoce como pre-pro-B (o 
fracción A), en el cual ambas cadenas se encuentran 
en	la	configuración	germinal.		En	la	siguiente	fase	de	
desarrollo, conocida como pro-B (compuesta por las 
fracciones B y C), se inicia el reordenamiento de la 
cadena pesada, que tiene lugar de forma secuencial, 
así, primero reordenan los segmentos D
H
 a J
H
, seguidos 
por el reordenamiento de los segmentos V a DJ
H
.  Una 
vez completado el reordenamiento de la cadena pesada, 
la célula pasa al siguiente estadío de diferenciación 
pre-B (compuesto por las fracciones C’ y D) en el que 
empieza el reordenamiento de la cadena ligera, V a 
J
L
.  Cuando ambas cadenas han reordenado, la célula 
se convierte en una célula inmadura B (o fracción E), 
caracterizada	por	la	expresión	de	IgM	en	su	superficie.	
Todas estas fases de diferenciación tienen lugar en 
la médula ósea (MO), pero las células inmaduras B 
migran a la periferia, donde están sujetas a un proceso 
de selección tras el cual las células supervivientes 
se convierten en células maduras B, caracterizadas 
por la expresión de los marcadores IgM e IgD en 
su	 superficie.	 	Los	 estadíos	 de	 diferenciación	 de	 los	
linfocitos B, están caracterizados por la expresión en 
membrana de distintos marcadores celulares como son 
B220, CD43, CD19, IgM e IgD. 
La generación de linfocitos maduros B requiere 
una serie de decisiones de destino celular en las cuales 
se han descrito varios factores de transcripción que 
juegan un papel relevante.  Entre todos ellos, por lo 
menos cinco han demostrado ser esenciales para el 
desarrollo de los linfocitos B.  Éstos son: PU.1, Ikaros, 
E2A, EBF (early cell factor) , Pax 5 (paired domain 
5).  PU.1 e Ikaros son necesarios para la formación 
de los progenitores linfoides (Medina et al., 2004), 
E2A y EBF son importantes en los estadíos tempranos 
de diferenciación de los linfocitos B (Medina et al., 
2004) y el factor de transcripción Pax-5 desempeña 
un papel crítico en el compromiso hacia linaje B y 
diferenciación de los linfocitos B (Nutt et al., 1999) 
.  Pax-5 regula la diferenciación de las células B 
activando	genes	que	confieren	identidad	B	como	son	
cd19 (Kozmik et al., 1992), blnk (Schebesta et al., 
2002), cd79a (Fitzsimmons et al., 1996) y reprimiendo 
genes de linaje T como notch-1 (Souabni et al., 2002). 
Algunos tumores presentan una desregulación de 
la expresión de Pax-5.  En este sentido, Pax-5 se 
encuentra sobreexpresado en varios linfomas Non-
Hodgkin que presentan translocaciones que implican 
a los loci de Pax-5 y IgH (Souabni et al., 2007; Zhang 
et al., 2003) . 
La función del proto-oncogén c-myc en 
la diferenciación de los linfocitos B ha sido poco 
estudiada.  De todos los miembros de la familia Myc, 
sólo c- y N-Myc se expresan en los linfocitos B.  c-myc 
se expresa a diferentes niveles durante el desarrollo de 
los linfocitos B: su expresión empieza en el estadío 
por-B y es inducida en respuesta a citoquinas, como 
IL-7 (Morrow et al., 1992),  se expresa junto con 
N-myc en las células pre-B, y en células B inmaduras y 
maduras tras su activación.  Estudios en líneas celulares 
de linfocitos, han demostrado que la desregulación 
de c-Myc induce la muerte celular por apoptosis 
(Thompson, 1998). Estudios in vivo, han demostrado 
que la sobreexpresión de c-Myc en linfocitos B, 
resulta en una linfopoiesis B anómala caracterizada 
por un incremento en el número de linfocitos pro- y 
pre-B y una reducción de las poblaciones B inmaduras 
y maduras de la médula ósea y en una reducción de 
los linfocitos B del bazo (Iritani and Eisenman, 1999). 
Asimismo, estos linfocitos tienen un tamaño mayor y 
este aumento está en relación con un incremento en la 
síntesis de proteínas.
El campo de c-Myc ha carecido, hasta hace 
unos años de modelos in vivo basados en pérdida de 
función, debido a la letalidad embrionaria (día 9-10) 
del KO en línea germinal de ratón (Davis et al., 1993) 
. La generación de un modelo condicional de ratón 
(de Alboran et al., 2001) que permite la inactivación 
funcional de c-myc  mediante la utilización del sistema 
cre-lox (Gu et al., 1993; Thomas and Capecchi, 1987) 
ha sido de gran ayuda para estudiar su función in vivo 
en individuos adultos.  Estudios realizados en linfocitos 
B	primarios	 deficientes	 en	 c-Myc, han revelado que 
el proto-oncogén c-myc juega un papel determinante 
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en	 la	fisiología	de	 los	 linfocitos	B	maduros.	 	 c-Myc	
regula la proliferación celular a través del inhibidor 
de ciclo celular P27 (de Alboran et al., 2001) y 
participa, de forma sorprendente, tanto en la muerte 
celular programada como en la muerte espontánea en 
linfocitos maduros (de Alboran et al., 2003).
7.2. Resultados
7.2.1. Generación de modelos animales para el 
estudio de la función de c-Myc en el desarrollo de 
los linfocitos B
 Para llevar a cabo el estudio de la función de 
c-Myc en el desarrollo de los linfocitos B generamos 
dos modelos animales de ratón en los que la inactivación 
de este proto-oncogén tiene lugar de forma constitutiva 
o inducible.
 7.2.1.1. Modelo constitutivo: c--mycfl/fl;- mb--
1cre/+
 
Los ratones c--mycfl/fl  se cruzaron con los 
ratones mb--1cre/+ (Hobeika et al., 2006), que expresan 
la recombinasa cre bajo el promotor del gen mb--1 el 
cual	codifica	la	subunidad	Igαβ	del	pre-receptor	de	los	
linfocitos B (pre-BCR). Estos ratones inactivan c--myc 
de	forma	constitutiva	y	específicamente	en	las	células	
pro-B.	Para	poder	seleccionar	las	células	deficientes	en	
c--Myc	por	la	expresión	de	green	fluorescent	protein	
(GFP), los ratones c--mycfl/fl;- mb--1cre/+ se cruzaron 
con los ratones Rosa26-egfp (Mao et al., 2001), que 
expresan la proteína GFP bajo el promotor endógeno 
del gen rosa26.
 7.2.1.2. Modelo inducible: c-mycfl/fl;- 
mx-cre+
Los ratones c-mycfl/fl  se cruzaron con los ratones 
transgénicos para cre bajo el promotor inducible por 
interferon mx.  La inoculación de interferon alfa o 
el ácido polyinosinic-polycytidylic (pIpC), permite 
inducir la inactivación de c-myc en médula ósea (MO) 
e hígado (Kuhn et al., 1995).
7.2.2. c-Myc es necesario para el desarrollo de los 
linfocitos B
 Durante el proceso de diferenciación de 
linfocitos B se produce el reordenamiento de los 
genes del receptor de las células B (BCR).  Este 
reordenamiento	 de	 los	 genes	 del	 BCR	 define	 los	
estadíos de diferenciación de linfocitos B, pro- y 
pre-B (B220+IgM-), inmaduros (B220loIgM+) y 
células B maduras (B220hiIgM+).  La inactivación 
de c-Myc en linfocitos B inmaduros en la MO de los 
ratones c-mycfl/fl;-mb-1cre/+provoca un bloqueo en la 
diferenciación de linfocitos B en el estadío B220+IgM-. 
La caracterización de los linfocitos B presentes en el 
bazo de los ratones c-mycfl/fl;-mb-1cre/+, mostró que 
tanto los números relativos y absolutos mostraban una 
reducción de la población de células B220+IgM+ en 
comparación con los ratones control.
Por otro lado, los ratones c-mycfl/fl;-mx-cre+ 
mostraron una diferenciación anómala de los linfocitos 
B caracterizada por una disminución de las poblaciones 
B220+IgM-, y B220loIgM+.
La MO de ratones c-mycfl/fl;-mb-1cre/+fue 
deplecionada de las células IgM positivas y puesta 
en cultivo en condiciones que favorecen la expansión 
de linfocitos B in vitro.  Estos cultivos no generaron 
células IgM+, indicando que las células B220+IgM+ 
presentes en el bazo de los ratones c-mycfl/fl;-mb-1cre/+ 
no podían ser generadas en ausencia de c-Myc.
7.2.3. c-Myc es necesario para la supervivencia de los 
linfocitos pro-, pre- y los linfocitos B inmaduros
 La inactivación de c-Myc en la MO de los 
ratones c-mycfl/fl;-mb-1cre/+ y c-mycfl/fl;-mx-cre+ produce 
un aumento en los niveles de apoptosis de los linfocitos 
B220+IgM- en el caso de los ratones c-mycfl/fl;-mb-1cre/+, 
y de los linfocitos B220+IgM-   y B220loIgM+ en ratones 
c-mycfl/fl;-mx-cre+. 
7.2.4. Los linfocitos B son capaces de proliferar en 
ausencia de c-Myc 
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 Ensayos de incorporación de BrdU en los 
linfocitos B, mostraron que las células B220+IgM- de 
ratones c-mycfl/fl;-mb-1cre/+, y los linfocitos B220+IgM-  
y B220loIgM+ de ratones c-mycfl/fl;-mx-cre+ proliferan 
en ausencia de c-Myc, aunque menos que las mismas 
células de ratones control.
7.2.5. Patrón de expresión génica en linfocitos B 
inmaduros y deficientes en c-Myc
Utilizando “real time” PCR observamos que 
las	células	B	deficientes	en	c-Myc	presentaban	niveles	
de expresión reducidos de e2a, ebf1 y pax5. En el caso 
de Pax5, no sólo sus niveles de expresión estaban 
disminuidos sino que también los de sus genes diana 
como son blnk, n-myc, Igα e Igβ.
7.2.6. Los linfocitos B inmaduros deficientes 
en c-Myc presentan una recombinación V(D)J 
anómala
Mediante PCR semicuantitativa y el uso 
de	 oligonucleótidos	 específicos	 para	 la	 detección	
de segmentos reordenados D
H
-J
H, 
V
Hproximal
-DJ
H
 and 
V
Hdistal
-DJ
H
, estudiamos la recombinación V(D)J 
en células B220+IgM- sorteadas de ratones c-mycfl/
fl;-mb-1cre/+ y ratones control.  Los resultados mostraron 
que	 los	 linfocitos	pro-	y	pre-B	deficientes	en	c-Myc	
presentaban una recombinación V(D)J anómala.
7.2.7. La células pro-y pre-B deficientes en c-Myc 
tienen una expresión en membrana de CD19 y pre-
BCR reducida
 El estudio de la expresión en membrana de los 
marcadores CD19 y pre-BCR, mediante citometría de 
flujo,	mostró	que	las	células	pro-	y	pre-B	deficientes	
en c-Myc, presentan una expresión reducida de dichos 
marcadores en relación a su expresión en las células 
de ratones control.
7.2.8. Los linfocitos B deficientes en c-Myc no 
son capaces de generar células de otros linajes 
hematopoyéticos in vitro
 Se llevaron a cabo ensayos clonogénicos 
para estudiar la capacidad de los linfocitos pro- y 
pre-B de los ratones c-mycfl/fl;-mb-1cre/+ de generar 
células de linaje eritroide, granulocítico/mieloide y 
linfoide. Los resultados mostraron que los linfocitos 
pro-B	 deficientes	 en	 c-Myc	 sólo	 fueron	 capaces	 de	
generar células de linaje B, indicando que son células 
comprometidas a ese linaje.
7.3. Expresión ectópica de Pax5 en linfocitos B 
deficientes en c-Myc
 Con	el	fin	de	estudiar	si	la	expresión	ectópica	
de	Pax5	en	células	deficientes	en	c-Myc	era	suficiente	
para rescatar la diferenciación anómala de los linfocitos 
B, cruzamos los ratones Ikneo/+ (que expresan el gen 
pax5 bajo el promotor de ikaros endógeno) con las 
cepas de ratón mencionadas anteriormente: c-mycfl/
fl;-mb-1cre/+ y c-mycfl/fl;-mx-cre+.
7.3.1. Los ratones Ikneo/+; c-mycfl/fl;-mb-1cre/+ presentan 
diferenciación anómala de los linfocitos B
	 La	 caracterización	por	 citometría	de	flujo	de	
las distintas poblaciones de linfocitos B presentes en 
la MO de los ratones Ikneo/+; c-mycfl/fl;-mb-1cre/+, mostró 
que estos linfocitos se encontraban bloqueados en el 
estadío de diferenciación B220+IgM-.  Asimismo, la 
expresión	en	 superficie	del	marcador	CD19	en	estas	
células, estaba disminuida en los ratones Ikneo/+; c-mycfl/
fl;-mb-1cre/+ en comparación con la expresión en las 
mismas células de los ratones control.
 Células de la MO de los ratones Ikneo/+; c-mycfl/
fl;-mb-1cre/+ , fueron deplecionadas de IgM, y se 
cultivaron en condiciones que favorecen la expansión 
de los linfocitos B. Los resultados mostraron que 
dichas células fueron incapaces de generar células 
B220+IgM+.  Los resultados muestran que los ratones 
Ikneo/+; c-mycfl/fl;-mb-1cre/+ presentan un bloqueo en la 
diferenciación de los linfocitos B.
 Mediante RT-PCR cuantitativa, analizamos la 
expresión génica de e2a, ebf1 y pax5 en estas células. 
Los resultados obtenidos demostraron que estas células 
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no llegan a expresar pax5, lo que podría explicar el 
bloqueo en la diferenciación de los linfocitos B en los 
ratones Ikneo/+; c-mycfl/fl;-mb-1cre/+.
7.3.2. Rescate de la diferenciación de los linfocitos 
B in vivo en los ratones Ikneo/+; c-mycfl/fl; mx-cre+
En la MO de los ratones Ikneo/+; c-mycfl/
fl; mx-cre+, inoculados previamente con pIpC, 
observamos un aumento, tanto en números absolutos 
como relativos, de las poblaciones B220+IgM- y 
B220loIgM+, en comparación con la MO de los ratones 
c-mycfl/fl; mx-cre+. Asismismo, también observamos 
un rescate en la expresión en membrana del 
marcador CD19 en las células B220+IgM- de ratones 
Ikneo/+; c-mycfl/fl; mx-cre+.
 El cultivo de células de la MO de los ratones 
Ikneo/+; c-mycfl/fl; mx-cre+, previamente deplecionadas 
de IgM, en condiciones favorecedoras de la expansión 
de los linfocitos B, generó células B220+IgM+. Los 
resultados muestran que los ratones Ikneo/+; c-mycfl/
fl; mx-cre+ presentan un rescate en el bloqueo de la 
diferenciación de los linfocitos B.
 El estudio de la expresión génica de e2a, ebf1 
y pax5 en células B220+IgM- de ratones Ikneo/+; c-mycfl/
fl; mx-cre+, mostró que los niveles de expresión de 
estos genes estaban modulados positivamente en 
comparación con las mismas células de los ratones 
c-mycfl/fl; mx-cre+. 
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7.4. Conclusiones
1.  c-myc es necesario para la supervivencia y el mantenimiento de los linfocitos pro-B, pre-B y B inmaduros.
2.  Los linfocitos pro-B, pre-B y B inmaduros son capaces de proliferar en ausencia de c-myc.
3. La inactivación de c-myc en los linfocitos pro-B y pre-B de los ratones c-mycfl/fl; mb-1cre/+ provoca una 
recombinación V(D)J anómala 
4.  Los niveles de expresión génica de los factores de transcripción E2A, EBF and Pax5 se encuentran disminuidos 
en las células B220+IgM- de los ratones c-mycfl/fl; mb-1cre/+.
5.  Los niveles de expresión de los marcadores de membrana CD19 y pre-BCR están reducidos en los linfocitos 
pro-B	y	pre-B	deficientes	en	c-Myc.	
6.  La expresión ectópica de Pax5 controlada por el promotor del gen Ikaros endógeno, promueve la diferenciación 
de los linfocitos B del estadío B220+IgM- al B220loIgM+ in vitro en los ratones Ikneo/+; c-mycfl/fl; mx-cre+.
7. La expresión ectópica de Pax5 en los ratones Ikneo/+; c-mycfl/fl; mx-cre+ rescata el programa transcripcional 
formado por los factores de transcripción E2A/EBF/Pax5.
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